<SEC-DOCUMENT>0001193125-20-128818.txt : 20200430
<SEC-HEADER>0001193125-20-128818.hdr.sgml : 20200430
<ACCEPTANCE-DATETIME>20200430162213
ACCESSION NUMBER:		0001193125-20-128818
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20200427
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200430
DATE AS OF CHANGE:		20200430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		20835980

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d857739d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:biib="http://www.biogenidec.com/20200427" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2020-04-27_to_2020-04-27">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2020-04-27_to_2020-04-27">0000875045</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="biib-20200427.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2020-04-27_to_2020-04-27"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-04-27</xbrli:startDate> <xbrli:endDate>2020-04-27</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="font-size:10pt;width:8.5in;margin:0 auto"> <p style="font-family:Arial;font-weight:bold;text-align:center;font-size:14pt;margin-bottom:0pt;margin-top:0pt">UNITED STATES</p> <p style="font-family:Arial;font-weight:bold;text-align:center;font-size:14pt;margin-bottom:0pt;margin-top:0pt">SECURITIES AND EXCHANGE COMMISSION</p> <p style="font-family:Arial;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">Washington, D.C. 20549</p> <p style="font-family:Arial;font-weight:bold;text-align:center;font-size:18pt;margin-bottom:0px;margin-top:12pt">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2020-04-27_to_2020-04-27">8-K</ix:nonNumeric></p> <p style="font-family:Arial;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0px;margin-top:12pt">CURRENT REPORT</p> <p style="font-family:Arial;font-weight:bold;text-align:center;font-size:12pt;margin-bottom:0pt;margin-top:0pt">PURSUANT TO SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p> <p style="font-family:Arial;text-align:center;font-size:12pt;margin-bottom:0px;margin-top:16pt">Date of Report (Date of earliest event reported): <span style="font-weight:Bold;font-style:normal"><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2020-04-27_to_2020-04-27" format="ixt:datemonthdayyearen">April 27, 2020</ix:nonNumeric></span></p> <p style="font-family:Arial;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0px;margin-top:6pt">
<img alt="IMAGE" src="g857739g0430030203730.jpg" /></p> <p style="font-family:Arial;font-weight:bold;text-align:center;font-size:24pt;margin-bottom:0px;margin-top:6pt"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2020-04-27_to_2020-04-27">Biogen Inc.</ix:nonNumeric> </p> <p style="font-family:Arial;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Exact name of registrant as specified in its charter)</p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:34%;"></td>
<td></td>
<td style="width:33%;"></td>
<td style="width:1%;"></td>
<td style="width:33%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Arial;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2020-04-27_to_2020-04-27" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Arial;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2020-04-27_to_2020-04-27">0-19311</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Arial;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2020-04-27_to_2020-04-27">33-0112644</ix:nonNumeric></p></td></tr>
<tr style="font-size:1pt;">
<td style="height:5px;">&#160;</td>
<td style="height:5px;">&#160;</td>
<td style="height:5px;">&#160;</td>
<td style="height:5px;">&#160;</td>
<td style="height:5px;">&#160;</td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Arial;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(State or other jurisdiction of incorporation)</p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Arial;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Commission File Number)</p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Arial;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(I.R.S. Employer Identification No.)</p></td></tr></table>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:16pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:99%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Arial;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2020-04-27_to_2020-04-27">225 Binney Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2020-04-27_to_2020-04-27">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2020-04-27_to_2020-04-27" format="ixt-sec:stateprovnameen">Massachusetts</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2020-04-27_to_2020-04-27">02142</ix:nonNumeric></p></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Arial;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Address of principal executive offices; Zip Code)</p></td></tr></table> <p style="font-family:Arial;text-align:center;font-size:10pt;margin-bottom:0px;margin-top:16pt">Registrant&#8217;s telephone number, including area code: <span style="font-weight:Bold;font-style:normal"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2020-04-27_to_2020-04-27">(617)</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2020-04-27_to_2020-04-27">679-2000</ix:nonNumeric></span></p> <p style="font-family:Arial;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0px;margin-top:6pt">Not Applicable</p> <p style="font-family:Arial;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">(Former name or former address, if changed since last report.)</p> <p style="font-family:Arial;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-family:Arial;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:14pt"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2020-04-27_to_2020-04-27" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p> <p style="font-family:Arial;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2020-04-27_to_2020-04-27" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p> <p style="font-family:Arial;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2020-04-27_to_2020-04-27" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p> <p style="font-family:Arial;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt"> <span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2020-04-27_to_2020-04-27" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p> <p style="font-family:Arial;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Securities registered pursuant to Section 12(b) of the Act:</p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:8pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td style="width:35%;"></td>
<td style="width:1%;"></td>
<td style="width:33%;"></td>
<td style="width:1%;"></td>
<td style="width:32%;"></td></tr>
<tr style="page-break-inside:avoid;font-size:8pt;">
<td style="border-bottom:1pt solid #000000;white-space:nowrap;vertical-align:bottom;"> <p style="font-family:Arial;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Title of each class</p> <p style="font-size:1pt;margin-bottom:1pt;margin-top:0">&#160;</p></td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Arial;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Trading Symbol(s)</p> <p style="font-size:1pt;margin-bottom:1pt;margin-top:0">&#160;</p></td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="border-bottom:1pt solid #000000;vertical-align:bottom;"> <p style="font-family:Arial;text-align:center;font-size:8pt;margin-bottom:0pt;margin-top:0pt">Name of each exchange on which registered</p> <p style="font-size:1pt;margin-bottom:1pt;margin-top:0">&#160;</p></td></tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Arial;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2020-04-27_to_2020-04-27">Common Stock, $0.0005 par value</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Arial;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2020-04-27_to_2020-04-27">BIIB</ix:nonNumeric></p></td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Arial;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2020-04-27_to_2020-04-27" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></p></td></tr></table> <p style="font-family:Arial;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p> <p style="font-family:Arial;text-align:right;font-size:10pt;margin-bottom:0px;margin-top:18pt">Emerging growth company&#32;<span style="font-family:Times New Roman;font-weight:normal"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2020-04-27_to_2020-04-27" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></p> <p style="font-family:Arial;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:18pt">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#32;<span style="font-family:Times New Roman;font-weight:normal">&#9744;</span></p> <div></div> <p style="margin-top:1em;margin-bottom:0em"></p></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

 <div style="font-size:10pt;width:8.5in;margin:0 auto">
<table cellspacing="0" cellpadding="0" border="0" style="color:#0075C9;font-family:Arial;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:12pt;{ &quot;1&quot;: &quot;color:red&quot; }:2;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:13%;vertical-align:top;white-space:nowrap;">Item&#160;8.01 </td>
<td style="color:#0075C9;font-family:Arial;font-weight:bold;text-align:left;font-size:12pt;{ &quot;1&quot;: &quot;color:red&quot; }:2;margin-bottom:0pt;margin-top:0pt;">Other Events.</td> </tr> </table> <p style="font-family:Arial;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">On April&#160;27, 2020, Biogen Inc. (the &#8220;Company&#8221;) entered into an Underwriting Agreement (the &#8220;Underwriting Agreement&#8221;) with Goldman Sachs&#160;&#038; Co. LLC, BofA Securities, Inc. and J.P. Morgan Securities LLC, as representatives of the several underwriters named in Schedule I thereto, relating to the issuance and sale of $3.0&#160;billion aggregate principal amount of notes, consisting of $1.5&#160;billion aggregate principal amount of 2.250% Senior Notes due May&#160;1, 2030 (the &#8220;2030 Notes&#8221;) and $1.5&#160;billion aggregate principal amount of 3.150% Senior Notes due May&#160;1, 2050 (together with the 2030 Notes, the &#8220;Notes&#8221;). </p> <p style="font-family:Arial;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">On April&#160;30, 2020, the Company completed the issuance and sale of the Notes. The Notes were issued pursuant to an indenture, dated September&#160;15, 2015 (the &#8220;Base Indenture&#8221;), as supplemented by the Second Supplemental Indenture, dated April&#160;30, 2020 (the &#8220;Second Supplemental Indenture&#8221; and, together with the Base Indenture, the &#8220;Indenture&#8221;), by and between the Company and U.S. Bank National Association, as trustee. </p> <p style="font-family:Arial;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">The Notes were registered pursuant to an automatic shelf registration statement on Form <span style="white-space:nowrap">S-3</span> under the Securities Act of 1933, as amended, (Registration Statement No.<span style="white-space:nowrap">&#160;333-237819)</span> (the &#8220;Registration Statement&#8221;) that was filed with the Securities and Exchange Commission on April&#160;24, 2020. </p> <p style="font-family:Arial;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">The Notes are the Company&#8217;s senior unsecured obligations. The Notes may be redeemed at the Company&#8217;s option at any time at 100% of the principal amount plus accrued interest and, until a specified period before maturity, a specified make-whole amount. The Notes contain a <span style="white-space:nowrap">change-of-control</span> provision that, under certain circumstances, may require the Company to offer to purchase the Notes at a price equal to 101% of the principal amount plus accrued and unpaid interest to the date of repurchase. </p> <p style="font-family:Arial;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">The Company intends to use the net proceeds from the sale of the Notes to redeem in full $1.5&#160;billion in aggregate principal amount of its outstanding 2.90% Senior Notes due September&#160;15, 2020, and all accrued and unpaid interest thereon, to fund, together with cash on hand, repurchases of its common stock under the Company&#8217;s stock repurchase plans and for working capital and other general corporate purposes. </p> <p style="font-family:Arial;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:12pt">A copy of the Underwriting Agreement and the Second Supplemental Indenture are attached hereto as Exhibits 1.1 and 4.2, respectively, and are incorporated herein by reference. The Base Indenture, included as Exhibit 4.1 of the Company&#8217;s Current Report on Form <span style="white-space:nowrap">8-K,</span> filed on September&#160;16, 2015, is incorporated herein by reference. The descriptions of the Underwriting Agreement and the Indenture are summaries only and are qualified in their entirety by the terms of the Underwriting Agreement and Indenture, respectively. </p> <div></div> <p style="margin-top:1em;margin-bottom:0em"></p>
 </div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

 <div style="font-size:10pt;width:8.5in;margin:0 auto">
<table cellspacing="0" cellpadding="0" border="0" style="color:#0075C9;font-family:Arial;font-weight:bold;border-collapse:collapse;text-align:left;width:100%;font-size:12pt;{ &quot;1&quot;: &quot;color:red&quot; }:2;margin-bottom:0pt;margin-top:0pt;border:0;">
<tr style="page-break-inside:avoid;">
<td style="width:13%;vertical-align:top;white-space:nowrap;">Item&#160;9.01 </td>
<td style="color:#0075C9;font-family:Arial;font-weight:bold;text-align:left;font-size:12pt;{ &quot;1&quot;: &quot;color:red&quot; }:2;margin-bottom:0pt;margin-top:0pt;">Financial Statements and Exhibits.</td> </tr> </table> <p style="font-family:Arial;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0px;margin-top:6pt">(d)&#160;Exhibits </p>
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:100%;margin-bottom:0px;margin-top:12pt;margin-left:auto;margin-right:auto">
<tr>
<td></td>
<td></td>
<td></td>
<td style="width:7%;"></td>
<td style="width:90%;"></td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td colspan="2" style="white-space:nowrap;vertical-align:bottom;text-align:center;"> <p style="font-family:Arial;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Exhibit </p> <p style="font-family:Arial;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border-bottom:1pt solid #000000;display:inline-block">&#160;&#160;&#160;&#160;No.&#160;&#160;&#160;&#160;</p> </td>
<td style="white-space:nowrap;vertical-align:bottom;font-weight:bold;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;display:inline-block;">&#160;</td>
<td style="vertical-align:bottom;">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:center;"> <p style="font-family:Arial;font-weight:bold;text-align:center;font-size:10pt;margin-bottom:0pt;margin-top:0pt;border-bottom:1pt solid #000000;display:inline-block">Description </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Arial;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Arial;font-size:10pt;margin-bottom:0pt;margin-top:0pt">&#160;&#160;1.1 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Arial;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d857739dex11.htm">Underwriting Agreement, dated April&#160;27, 2020, by and among the Company, Goldman Sachs&#160;&#038; Co. LLC, BofA Securities, Inc. and J.P. Morgan Securities LLC, as representatives of the several underwriters named in Schedule I thereto. </a> </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Arial;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Arial;font-size:10pt;margin-bottom:0pt;margin-top:0pt">&#160;&#160;4.1 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Arial;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="http://www.sec.gov/Archives/edgar/data/875045/000119312515320650/d78596dex41.htm">Indenture, dated September<span style="text-decoration:underline"></span>&#160;15, 2015, between Biogen Inc. and U.S. Bank National Association (incorporated by reference to Exhibit 4.1 to the Company&#8217;s Current Report on Form<span style="text-decoration:underline"></span>&#160;8-K<span style="text-decoration:underline"></span>&#160;filed on September<span style="text-decoration:underline"></span>&#160;16, 2015)</a>. </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Arial;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Arial;font-size:10pt;margin-bottom:0pt;margin-top:0pt">&#160;&#160;4.2 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Arial;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d857739dex42.htm">Second Supplemental Indenture, dated April&#160;30, 2020, between the Company and U.S. Bank National Association, including the forms of Global Notes attached as Exhibit A and Exhibit B, respectively, thereto. </a> </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Arial;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Arial;font-size:10pt;margin-bottom:0pt;margin-top:0pt">&#160;&#160;5.1 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Arial;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d857739dex51.htm">Opinion of Foley Hoag LLP as to the validity of the Notes. </a> </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Arial;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Arial;font-size:10pt;margin-bottom:0pt;margin-top:0pt">23.1 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Arial;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt"> <a href="d857739dex51.htm">Consent of Foley Hoag LLP (included in Exhibit 5.1). </a> </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td>
<td style="height:8px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="white-space:nowrap;vertical-align:top;padding:0;font-family:Arial;font-size:10pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;padding:0;text-align:left"> <p style="font-family:Arial;font-size:10pt;margin-bottom:0pt;margin-top:0pt">104 </p> </td>
<td style="white-space:nowrap;vertical-align:top;padding-right:2pt;margin-bottom:0pt;margin-top:0pt;">&#160;</td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Arial;margin-left:0.00em;text-align:left;text-indent:0.00em;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Cover Page Interactive Data File (embedded within the Inline XBRL document) </p> </td> </tr> </table> <div></div> <p style="margin-top:1em;margin-bottom:0em"></p>
 </div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

 <div style="font-size:10pt;width:8.5in;margin:0 auto"> <p style="color:#0075C9;font-family:Arial;font-weight:bold;text-align:center;font-size:12pt;{ &quot;1&quot;: &quot;color:red&quot; }:2;margin-bottom:0pt;margin-top:0pt">SIGNATURES </p> <p style="font-family:Arial;text-align:left;text-indent:4%;font-size:10pt;margin-bottom:0px;margin-top:12pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <div style="float:right;width:100%">
<table cellspacing="0" cellpadding="0" border="0" style="font-size:10pt;border-collapse:separate;border-spacing:0;width:40%;margin-bottom:0px;margin-top:20pt;margin-left:auto;margin-right:0px">
<tr>
<td style="width:13%;"></td>
<td style="width:2%;"></td>
<td style="width:85%;"></td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td colspan="3" style="vertical-align:top;padding:0;"> <p style="font-family:Arial;font-weight:bold;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">BIOGEN INC. </p> </td> </tr>
<tr style="font-size:1pt;">
<td style="height:27px;">&#160;</td>
<td style="height:27px;">&#160;</td>
<td style="height:27px;">&#160;</td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Arial;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">By: </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Arial;text-align:left;margin-bottom:1pt;font-size:10pt;margin-top:0pt;border-bottom:1px solid #000000">&#160;/s/ Michael Dambach </p> </td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Arial;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Name: </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Arial;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">&#160;Michael Dambach </p> </td> </tr>
<tr style="page-break-inside:avoid;font-size:10pt;">
<td style="vertical-align:top;padding:0;"> <p style="font-family:Arial;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">Title: </p> </td>
<td style="vertical-align:top;">&#160;</td>
<td style="vertical-align:top;padding:0;"> <p style="font-family:Arial;text-align:left;font-size:10pt;margin-bottom:0pt;margin-top:0pt">&#160;Vice President, Treasurer </p> </td> </tr> </table> </div> <div style="clear:both"></div> <p style="font-family:Arial;margin-left:0%;text-align:left;text-indent:0%;font-size:10pt;margin-bottom:0px;margin-top:16pt">Dated: April&#160;30, 2020 </p> <div></div> <p style="margin-top:1em;margin-bottom:0em"></p>
 </div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d857739dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Execution Version </B></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Biogen
Inc. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2.250% Senior Notes due 2030 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3.150% Senior Notes due 2050 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Underwriting Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">April&nbsp;27, 2020 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co.
LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As representatives of the several Underwriters </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">named in Schedule
I hereto, </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c/o</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Goldman Sachs&nbsp;&amp; Co. LLC </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">200 West Street </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New York, New York 10282-2198 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">BofA Securities, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">One Bryant Park </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New York, New York 10036-6728 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">J.P. Morgan Securities LLC </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">383 Madison Avenue </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">New York, New York 10179-0001 </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biogen Inc., a Delaware
corporation (the &#147;<B>Company</B>&#148;), proposes, subject to the terms and conditions stated herein, to issue and sell to Goldman Sachs&nbsp;&amp; Co. LLC, BofA Securities, Inc., J.P. Morgan Securities LLC and each of the other Underwriters
named in Schedule I hereto (the &#147;<B>Underwriters</B>&#148;), for whom Goldman Sachs&nbsp;&amp; Co. LLC, BofA Securities, Inc. and J.P. Morgan Securities LLC are acting as representatives (in such capacity, the
&#147;<B>Representatives</B>&#148;), the respective amounts set forth in Schedule I of $1,500,000,000 aggregate principal amount of the Company&#146;s 2.250% Senior Notes due 2030 (the &#147;<B>2030 Notes</B>&#148;) and $1,500,000,000 aggregate
principal amount of the Company&#146;s 3.150% Senior Notes due 2050 (the &#147;<B>2050 Notes</B>&#148; and, together with the 2030 Notes, the &#147;<B>Securities</B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;The Company represents and warrants to, and agrees with, each of the Underwriters that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Company meets the requirements for use of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under
the Act (as defined below); an &#147;<B>automatic shelf registration statement</B>&#148; as defined under Rule 405 under the Securities Act of 1933, as amended (the &#147;<B>Act</B>&#148;), on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT
STYLE="white-space:nowrap">No.&nbsp;333-</FONT> 237819) in respect of the Securities has been filed </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
with the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) not earlier than three years prior to the date hereof; such registration statement, and any post-effective
amendment thereto, became effective on filing; and no stop order suspending the effectiveness of such registration statement or any part thereof has been issued and, to the Company&#146;s knowledge, no proceeding for that purpose has been initiated
or threatened by the Commission, and no notice of objection of the Commission to the use of such registration statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Act has been received by the Company (the base
prospectus filed as part of such registration statement, in the form in which it has most recently been filed with the Commission on or prior to the date of this Agreement, is hereinafter called the &#147;<B>Basic Prospectus</B>&#148;; any
preliminary prospectus (including any preliminary prospectus supplement) relating to the Securities filed with the Commission pursuant to Rule 424(b) under the Act is hereinafter called a &#147;<B>Preliminary Prospectus</B>&#148;; the various parts
of such registration statement, including all exhibits thereto but excluding Form <FONT STYLE="white-space:nowrap">T-1</FONT> and including any prospectus supplement relating to the Securities that is filed with the Commission and deemed by virtue
of Rule 430B to be part of such registration statement, each as amended at the time such part of the registration statement became effective, are hereinafter collectively called the &#147;<B>Registration Statement</B>&#148;; the Basic Prospectus, as
amended and supplemented immediately prior to the Applicable Time (as defined in Section&nbsp;1(iii) hereof), is hereinafter called the &#147;<B>Pricing Prospectus</B>&#148;; the form of the final prospectus relating to the Securities filed with the
Commission pursuant to Rule 424(b) under the Act in accordance with Section&nbsp;5(i) hereof is hereinafter called the &#147;<B>Prospectus</B>&#148;; any reference herein to the Basic Prospectus, the Pricing Prospectus, any Preliminary Prospectus or
the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Act, as of the date of such prospectus; any reference to any
amendment or supplement to the Basic Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any post-effective amendment to the Registration Statement, any prospectus supplement relating to the Securities
filed with the Commission pursuant to Rule 424(b) under the Act and any documents filed under the Securities Exchange Act of 1934, as amended (the &#147;<B>Exchange Act</B>&#148;), and incorporated therein, in each case after the date of the Basic
Prospectus, such Preliminary Prospectus or the Prospectus, as the case may be; any reference to any amendment to the Registration Statement shall be deemed to refer to and include any annual report of the Company filed pursuant to Section&nbsp;13(a)
or 15(d) of the Exchange Act after the effective date of the Registration Statement that is incorporated by reference in the Registration Statement; and any &#147;<B>issuer free writing prospectus</B>&#148; as defined in Rule 433 under the Act
relating to the Securities is hereinafter called an &#147;<B>Issuer Free Writing Prospectus</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;No order preventing or suspending the use of any Preliminary Prospectus or any Issuer Free Writing
Prospectus has been issued by the Commission, and each Preliminary Prospectus, at the time of filing thereof, conformed in all material respects to the requirements of the Act and the Trust </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Indenture Act of 1939, as amended (the &#147;<B>Trust Indenture Act</B>&#148;), and the
rules and regulations of the Commission thereunder, and did not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the
circumstances under which they were made, not misleading; provided, however, that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with information furnished in writing to the
Company by an Underwriter through the Representatives expressly for use therein; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;For the
purposes of this Agreement, the &#147;<B>Applicable Time</B>&#148; is 3:45 p.m. (Eastern time) on the date of this Agreement; the Pricing Prospectus as supplemented by the final term sheet prepared and filed pursuant to Section&nbsp;5(i) hereof,
taken together (collectively, the &#147;<B>Pricing Disclosure Package</B>&#148;) as of the Applicable Time, did not include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading; provided, however, that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with information furnished
in writing to the Company by an Underwriter through the Representatives expressly for use therein; and each Issuer Free Writing Prospectus listed on Schedule II(a) hereto does not conflict with the information contained in the Registration
Statement, the Pricing Prospectus or the Prospectus and each such Issuer Free Writing Prospectus, as supplemented by and taken together with the Pricing Disclosure Package as of the Applicable Time, did not include any untrue statement of a material
fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that this representation and warranty shall not apply to
statements or omissions made in an Issuer Free Writing Prospectus in reliance upon and in conformity with information furnished in writing to the Company by an Underwriter through the Representatives expressly for use therein; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;The documents incorporated by reference in the Pricing Prospectus and the Prospectus, when they
became effective or were filed with the Commission, as the case may be, conformed in all material respects to the requirements of the Act or the Exchange Act, as applicable, and the rules and regulations of the Commission thereunder, and none of
such documents contained an untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein not misleading; any further documents so filed and incorporated by
reference in the Prospectus or any further amendment or supplement thereto, when such documents become effective or are filed with the Commission, as the case may be, will conform in all material respects to the requirements of the Act or the
Exchange Act, as applicable, and the rules and regulations of the Commission thereunder and will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements
therein not misleading; provided, however, that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with information furnished in writing to the Company by an Underwriter through
the Representatives expressly for use therein; and no such documents were filed with the Commission since the Commission&#146;s close of business on the business day immediately prior to the date of this Agreement and prior to the execution of this
Agreement, except as set forth on Schedule II(b) hereto; </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;The Registration Statement conforms, and the
Prospectus and any further amendments or supplements to the Registration Statement and the Prospectus will conform, in all material respects to the requirements of the Act and the Trust Indenture Act and the rules and regulations of the Commission
thereunder and do not and will not, as of the applicable effective date as to each part of the Registration Statement and as of the applicable filing date and the Time of Delivery (as defined in Section&nbsp;4(i) hereof) as to the Prospectus and any
amendment or supplement thereto, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; provided, however, that this representation
and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with information furnished in writing to the Company by an Underwriter through the Representatives expressly for use therein; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor any of its subsidiaries has sustained, since the date of the latest
audited financial statements included or incorporated by reference in the Pricing Prospectus, any material loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor
dispute or court or governmental action, order or decree, otherwise than as set forth or contemplated in the Pricing Prospectus; and, since the respective dates as of which information is given in the Registration Statement and the Pricing
Prospectus, there has not been any change in the capital stock (other than changes due to grants, exercises, and terminations under Company incentive plans referred to in the Pricing Prospectus and in the documents incorporated by reference therein
and other publicly announced share repurchase programs) or long-term debt of the Company or any of its subsidiaries or any material adverse change or any development that, in each case, is reasonably likely to result in a material adverse change, in
or affecting the general affairs, management, financial position, stockholders&#146; equity or results of operations of the Company and its subsidiaries taken as a whole (collectively, a &#147;<B>Material Adverse Effect</B>&#148;), otherwise than as
set forth or contemplated in the Pricing Prospectus; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;The Company and its subsidiaries have
good and marketable title in fee simple to all real property and good and marketable title to all personal property owned by them, in each case free and clear of all liens, encumbrances and defects except such as are described in the Pricing
Prospectus or such as would not reasonably be expected to have a Material Adverse Effect; and any real property and buildings held under lease by the Company and its subsidiaries are held by them under valid, subsisting and enforceable leases with
such exceptions as would not reasonably be expected to have a Material Adverse Effect; </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;&nbsp;&nbsp;&nbsp;The Company has been duly incorporated and is
validly existing as a corporation in good standing under the laws of the State of Delaware, with power and authority (corporate and other) to own its properties and conduct its business as described in the Pricing Prospectus, and has been duly
qualified as a foreign corporation for the transaction of business and is in good standing under the laws of each other jurisdiction in which it owns or leases properties or conducts any business so as to require such qualification, or is subject to
no material liability or disability by reason of the failure to be so qualified in any such jurisdiction except where failure would not reasonably be expected to have a Material Adverse Effect; and each significant subsidiary of the Company (as
defined in Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Act) (each, a &#147;<B>Significant Subsidiary</B>&#148;) has been duly incorporated and is validly existing as a
corporation, limited liability company or other entity in good standing under the laws of its jurisdiction of organization; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix)&nbsp;&nbsp;&nbsp;&nbsp;The Company has an authorized capitalization as set forth in the Pricing Prospectus and all of the
issued shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and <FONT STYLE="white-space:nowrap">non-assessable;</FONT> and all of the issued shares of capital stock, membership interests or
other capital securities of each Significant Subsidiary of the Company have been duly and validly authorized and issued, are (in the case of membership interests, to the extent applicable) fully paid and
<FONT STYLE="white-space:nowrap">non-assessable</FONT> and (except for directors&#146; qualifying shares) are owned directly or indirectly by the Company, free and clear of all liens, encumbrances, equities or claims; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;&nbsp;&nbsp;&nbsp;This Agreement has been duly authorized, executed and delivered by the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xi)&nbsp;&nbsp;&nbsp;&nbsp;The Securities have been duly authorized by the Company and, when executed and authenticated in
accordance with the provisions of the Indenture (as defined below) and delivered to and paid for by the Underwriters in accordance with the terms of this Agreement, will be valid and legally binding obligations of the Company enforceable against the
Company in accordance with their terms, subject to the Enforceability Exceptions (as defined below), and will be entitled to the benefits provided by the Indenture between the Company and U.S. Bank National Association (the
&#147;<B>Trustee</B>&#148;), dated as of September&nbsp;15, 2015 (the &#147;<B>Base Indenture</B>&#148;), as supplemented by a related supplemental indenture to be dated as of a date on or prior to the Time of Delivery (the &#147;<B>First
Supplemental Indenture</B>,&#148; and, together with the Base Indenture, the &#147;<B>Indenture</B>&#148;) between the Company and the Trustee, under which the Securities are to be issued, which, in the case of the Base Indenture, was filed as an
exhibit to the Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> of the Company filed on September&nbsp;16, 2015; the Indenture has been duly authorized by the Company and duly qualified under the Trust Indenture Act and, when
executed and delivered by the Company and the Trustee, will constitute, at the Time of Delivery, a valid and legally binding instrument, enforceable against the Company in accordance with its terms, subject, as to enforcement, to bankruptcy,
insolvency, fraudulent transfer, reorganization, moratorium and other laws of general applicability relating to or affecting creditors&#146; rights and to general equity principles (collectively, the &#147;<B>Enforceability Exceptions</B>&#148;);
and the Securities and the Indenture will conform to the descriptions thereof in the Pricing Disclosure Package and the Prospectus; </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xii)&nbsp;&nbsp;&nbsp;&nbsp;The issue and sale of the Securities and the
compliance by the Company with all of the provisions of the Securities, the Indenture and this Agreement and the consummation of the transactions herein and therein contemplated will not conflict with or result in a breach or violation of any of the
terms or provisions of, or constitute a default under, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its
subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject, except as would not reasonably be expected to have a Material Adverse Effect, nor will such action result in any violation of the
provisions of the Certificate of Incorporation or <FONT STYLE="white-space:nowrap">By-laws</FONT> of the Company or any statute or any order, rule or regulation of any court or governmental agency or body having jurisdiction over the Company or any
of its subsidiaries or any of their properties; and no consent, approval, authorization, order, registration or qualification of or with any such court or governmental agency or body is required for the issue and sale of the Securities or the
consummation by the Company of the transactions contemplated by this Agreement or the Indenture except such as have been, or prior to the Time of Delivery will be, obtained under the Act and the Trust Indenture Act and such consents, approvals,
authorizations, registrations or qualifications as may be required under state securities or Blue Sky laws in connection with the purchase and distribution of the Securities by the Underwriters; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiii)&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor any of its subsidiaries is in default in the performance or observance
of any obligation, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which it is a party or by which it or any of its properties may be bound other than as would not
reasonably be expected to have a Material Adverse Effect, or in violation of (i)&nbsp;its organizational documents or (ii)&nbsp;any statute or any order, rule or regulation of any court or governmental agency or body having jurisdiction over the
Company or any of its subsidiaries or any of their properties, except, in the case of clause (ii), for such violations that would not reasonably be expected to have a Material Adverse Effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xiv)&nbsp;&nbsp;&nbsp;&nbsp;The statements set forth in the Pricing Prospectus and the Prospectus under the caption
&#147;<B>Description of Notes</B>&#148;, insofar as they purport to constitute a summary of the terms of the Securities, under the caption &#147;<B>Material U.S. Federal Income Tax Considerations</B>&#148; and under the caption
&#147;<B>Underwriting</B>&#148;, insofar as they purport to describe the provisions of the laws and documents referred to therein, fairly summarize in all material respects such laws and documents; </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xv)&nbsp;&nbsp;&nbsp;&nbsp;Other than as set forth in the Pricing
Prospectus, there are no legal or governmental proceedings pending to which the Company or any of its subsidiaries is a party or of which any property of the Company or any of its subsidiaries is the subject which would, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect; and, to the Company&#146;s knowledge, no such proceedings are threatened or contemplated by governmental authorities or threatened by others; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvi)&nbsp;&nbsp;&nbsp;&nbsp;The Company is not and, after giving effect to the offering and sale of the Securities and the
application of the proceeds thereof, will not be an &#147;<B>investment company</B>&#148;, as such term is defined in the Investment Company Act of 1940, as amended (the &#147;<B>Investment Company Act</B>&#148;); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xvii)&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;(A) At the time of the filing of the Registration Statement, (B)&nbsp;at the time of
the most recent amendment thereto for the purposes of complying with Section&nbsp;10(a)(3) of the Act (whether such amendment was by post-effective amendment, incorporated report filed pursuant to Section&nbsp;13 or 15(d) of the Exchange Act or form
of prospectus) and (C)&nbsp;at the time the Company or any person acting on its behalf (within the meaning, for this clause only, of Rule 163(c) under the Act) made any offer relating to the Securities in reliance on the exemption of Rule 163 under
the Act, the Company was a &#147;<B>well-known seasoned issuer</B>&#148; as defined in Rule 405 under the Act; and (ii)&nbsp;at the earliest time after the filing of the Registration Statement that the Company or another offering participant made a
bona fide offer (within the meaning of Rule 164(h)(2) under the Act) of the Securities, and at the date hereof, the Company was not and is not an &#147;<B>ineligible issuer</B>&#148; as defined in Rule 405 under the Act; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xviii)&nbsp;&nbsp;&nbsp;&nbsp;PricewaterhouseCoopers LLP, who have certified certain financial statements of the Company and
its subsidiaries, and have audited the Company&#146;s internal control over financial reporting, are independent registered public accountants as required by the Act and the rules and regulations of the Commission thereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xix)&nbsp;&nbsp;&nbsp;&nbsp;The financial statements of the Company included in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, together with the related schedules and notes, present fairly, in all material respects, the financial position of the Company and its consolidated subsidiaries at the dates indicated and the statement of
operations, stockholders&#146; equity and cash flows of the Company and its consolidated subsidiaries for the periods specified; and said financial statements comply as to form with the accounting requirements of the Act and have been prepared in
conformity with U.S. generally accepted accounting principles (&#147;<B>GAAP</B>&#148;) applied on a consistent basis throughout the periods involved, except as may be stated in the related notes thereto; the supporting schedules, if any, present
fairly, in all material respects the information </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
required to be stated therein; the selected financial data and the summary financial information included in the Registration Statement, the Pricing Disclosure Package and the Prospectus present
fairly, in all material respects, the information shown therein and have been compiled on a basis consistent with that of the audited financial statements included therein; the interactive data in eXtensible Business Reporting Language incorporated
by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus fairly present the information called for in all material respects and have been prepared in accordance with the Commission&#146;s rules and guidelines
applicable thereto; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx)&nbsp;&nbsp;&nbsp;&nbsp;The Company and its subsidiaries, taken as a whole, maintain a system of
internal control over financial reporting (as such term is defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> under the Exchange Act) that complies with the requirements of the Exchange Act and has been designed by the Company&#146;s
principal executive officer and principal financial officer, or under their supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with GAAP. The Company&#146;s internal control over financial reporting is effective and the Company is not aware of any material weaknesses in its internal control over financial reporting; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxi)&nbsp;&nbsp;&nbsp;&nbsp;Since the date of the latest audited financial statements included or incorporated by reference
in the Pricing Prospectus, there has been no change in the Company&#146;s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial
reporting; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxii)&nbsp;&nbsp;&nbsp;&nbsp;The Company and its subsidiaries, taken as a whole, maintain a system of
internal accounting controls sufficient to provide reasonable assurances that: (A)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorization; (B)&nbsp;transactions are recorded as necessary to permit
preparation of financial statements in conformity with GAAP and to maintain accountability for assets; (C)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization; and (D)&nbsp;the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; the Company and its subsidiaries, taken as a whole, maintain an effective system of disclosure
controls and procedures (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> and Rule <FONT STYLE="white-space:nowrap">15d-15</FONT> under the Exchange Act) that are designed to ensure that the information required to be disclosed by
the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#146;s rules and forms, and is accumulated and communicated to the
Company&#146;s management, including its principal executive officer or officers and principal financial officer or officers, as appropriate, to allow timely decisions regarding disclosure; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxiii)&nbsp;&nbsp;&nbsp;&nbsp;Except as disclosed in the Pricing
Prospectus, and except where such failure would not reasonably be expected to have a Material Adverse Effect, the Company and its subsidiaries own, possess, license or have the right to use the patents, patent rights, licenses, inventions,
copyrights, <FONT STYLE="white-space:nowrap">know-how</FONT> (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks, trade names and other rights
or interests in items of intellectual property as are necessary for the operation and conduct of the businesses now operated by them (the &#147;<B>patent and proprietary rights</B>&#148;); and except as disclosed in the Pricing Prospectus, the
Company has not received notice of any infringement of or conflict with asserted rights of others with respect to any patent and proprietary rights, which infringement or conflict would reasonably be expected to result in a Material Adverse Effect;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxiv)&nbsp;&nbsp;&nbsp;&nbsp;Except as described in the Pricing Prospectus, the Company and its subsidiaries are in
compliance with all statutes, rules, regulations, ordinances, orders, decrees and guidance applicable to the ownership, testing, in humans or laboratory models, development, manufacture, formulation, packaging, processing, recordkeeping, use,
distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by or for the Company or any of its subsidiaries, except where the failure to so comply would not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxv)&nbsp;&nbsp;&nbsp;&nbsp;Except as disclosed in the Pricing Prospectus, and except as would not reasonably be expected to
have a Material Adverse Effect, (A)&nbsp;the Company and its subsidiaries&#146; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (including the data and information
of their respective customers, employees, suppliers, vendors and any third-party data maintained, processed or stored by the Company and its subsidiaries, and any such data processed or stored by third parties on behalf of the Company and its
subsidiaries) (collectively, &#147;<B>IT Systems</B>&#148;) are adequate for, and operate and perform as required in connection with, the operation of the business of the Company and its subsidiaries as currently conducted, free and clear of all
bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants; (B)&nbsp;the Company and its subsidiaries have used reasonable efforts to establish and maintain, and have established, maintained, implemented and complied with,
reasonable information technology, information security, cyber security and data protection controls, policies and procedures, including oversight, access controls, encryption, technological and physical safeguards and business continuity/disaster
recovery and security plans to protect against and prevent the breach, destruction, loss, disruption, outage, violation, unauthorized distribution, use, access, disablement, misappropriation or modification, or other compromise or misuse of or
relating to any information technology system or personal, personally identifiable, sensitive, confidential or regulated data (&#147;<B>Personal Data</B>&#148;) used in connection with the operation of the Company&#146;s and its subsidiaries&#146;
businesses (&#147;<B>Breach</B>&#148;); (C) to the knowledge of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the Company, there has been no such Breach nor any incidents under internal review or investigations relating to the same and the Company and its subsidiaries have not been notified of and have
no knowledge of any event or condition that would reasonably be expected to result in any such Breach; and (D)&nbsp;the Company and its subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules
and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and to the protection of such IT Systems from unauthorized use,
access, misappropriation or modification; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxvi)&nbsp;&nbsp;&nbsp;&nbsp;Except as disclosed in the Pricing Prospectus,
and except as would not reasonably be expected to have a Material Adverse Effect, (A)&nbsp;the Company and its subsidiaries have complied, and are presently in compliance with all applicable internal and external privacy policies, contractual
obligations, industry standards, applicable state, federal and international data privacy and security laws and regulations, including without limitation, the Health Insurance Portability and Accountability Act, the European Union General Data
Protection Regulation (EU 2016/679), and other statutes, judgments, orders, rules and regulations of any applicable court or arbitrator or other governmental or regulatory authority and any legal obligations regarding the collection, use, transfer,
import, export, storage, protection, disposal, disclosure or other processing by the Company and its subsidiaries of Personal Data (collectively, the &#147;<B>Data Security Obligations</B>&#148;); (B) neither the Company nor any of its subsidiaries
has received any notification of or complaint regarding, and are aware of any other facts that, individually or in the aggregate, would reasonably indicate <FONT STYLE="white-space:nowrap">non-compliance</FONT> by the Company or its subsidiaries
with any Data Security Obligation; (C)&nbsp;there is no pending or, to the knowledge of the Company, threatened, action, suit or proceeding by or before any applicable court or governmental agency, authority or body alleging <FONT
STYLE="white-space:nowrap">non-compliance</FONT> by the Company or any of its subsidiaries with any Data Security Obligation; (D)&nbsp;the Company and its subsidiaries have at all times taken steps reasonably necessary in accordance with industry
standard practices (including, without limitation, implementing and monitoring compliance with adequate measures with respect to technical and physical security) designed to ensure compliance in all material respects with their policies and
procedures relating to data privacy and security and the collection, use, transfer, import, export, storage, protection, disposal, disclosure or other processing of Personal Data that is subject to the Data Security Obligations (the
&#147;<B>Policies</B>&#148;) to protect such Personal Data against loss and unauthorized access, use, modification, disclosure or other misuse; and (E)&nbsp;the Company and its subsidiaries have made all disclosures of their then-current Policies to
their employees or other applicable third-party users or customers required by applicable laws and regulatory rules or requirements, and none of such disclosures made or contained in any Policy has, to the knowledge of the Company, been inaccurate
or in violation of any applicable laws and regulatory rules or requirements. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxvii)&nbsp;&nbsp;&nbsp;&nbsp;Except as described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus or as would not, singly or in the aggregate, result in a Material Adverse Effect, (A)&nbsp;neither the Company nor any of its subsidiaries is in violation of any federal, state, local or
foreign statute, law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or
protection of human health, the environment (including, without limitation, ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or
threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products (collectively, &#147;<B>Hazardous Materials</B>&#148;) or to the manufacture, processing, distribution, use,
treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &#147;<B>Environmental Laws</B>&#148;), (B) the Company and its subsidiaries have all permits, authorizations and approvals required under any applicable
Environmental Laws and are each in compliance with their requirements, (C)&nbsp;there are no pending or threatened administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation,
investigation or proceedings relating to any Environmental Law against the Company or any of its subsidiaries and (D)&nbsp;there are no events or circumstances that would reasonably be expected to form the basis of an order for <FONT
STYLE="white-space:nowrap">clean-up</FONT> or remediation, or an action, suit or proceeding by any private party or governmental entity, against or affecting the Company or any of its subsidiaries relating to Hazardous Materials or any Environmental
Laws; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxviii)&nbsp;&nbsp;&nbsp;&nbsp;Neither the Company nor any subsidiary of the Company has taken, directly or
indirectly, any action which is designed, or would be expected, to cause or result in, or which constitutes, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxix)&nbsp;&nbsp;&nbsp;&nbsp;There is and has been no failure on the part of the Company or any of the Company&#146;s
directors or officers, in their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated in connection therewith, including Section&nbsp;402 related to
loans and Sections 302 and 906 related to certifications; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxx)&nbsp;&nbsp;&nbsp;&nbsp;None of the Company, any of its
subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee, affiliate or other person acting on behalf of the Company or any of its subsidiaries has taken any action, directly or indirectly, that would result in a
violation by such persons of (i)&nbsp;the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the &#147;<B>FCPA</B>&#148;), including, without limitation, making use of the mails or any means or
instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give or authorization of the giving of anything
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
of value to any &#147;foreign official&#148; (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign political office, in
contravention of the FCPA, (ii)&nbsp;the U.K. Bribery Act 2010 (the &#147;<B>Bribery Act</B>&#148;) or (iii)&nbsp;any other applicable anti-bribery or anti-corruption law, and the Company, its subsidiaries and, to the knowledge of the Company, its
other affiliates have conducted their businesses in compliance with the FCPA, Bribery Act and any other applicable anti-bribery or anti-corruption law and have instituted and maintain policies and procedures designed to ensure continued compliance
therewith; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxi)&nbsp;&nbsp;&nbsp;&nbsp;The operations of the Company and its subsidiaries are and have been conducted
at all times in material compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable rules and
regulations thereunder (collectively, the &#147;<B>Money Laundering Laws</B>&#148;), and no action, suit or proceeding by or before any governmental entity involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is
pending or, to the knowledge of the Company, threatened; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xxxii)&nbsp;&nbsp;&nbsp;&nbsp;None of the Company, any of
its subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee, affiliate or other person acting on behalf of the Company or any of its subsidiaries is (A)&nbsp;an individual or entity (&#147;<B>Person</B>&#148;)
currently the subject or target of any sanctions administered or enforced by the United States Government, including, without limitation, the U.S. Department of the Treasury&#146;s Office of Foreign Assets Control, the U.S. Department of State and
including, without limitation, the designation as a &#147;specially designated national&#148; or &#147;blocked person,&#148; the United Nations Security Council, the European Union, Her Majesty&#146;s Treasury or other relevant sanctions authority
(collectively, &#147;<B>Sanctions</B>&#148;) or (B)&nbsp;located, organized or resident in a country or territory that is the subject or target of Sanctions; and neither the Company nor its subsidiaries will, directly or indirectly, use the proceeds
of the sale of the Securities, or lend, contribute or otherwise make available such proceeds to any subsidiaries, joint venture partners or other Person, to fund any activities of or business with any Person, or in any country or territory, that, at
the time of such funding, is the subject of Sanctions or in any other manner that will result in a violation by any Person (including any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;Subject to the terms and conditions herein set forth, the Company agrees to issue and sell to each of the
Underwriters, and each of the Underwriters agrees, severally and not jointly, to purchase from the Company, the principal amount of Securities set forth opposite the name of such Underwriter in Schedule I hereto at a purchase price of 99.523% of the
principal amount of the 2030 Notes and 98.299% of the principal amount of the 2050 Notes, plus, in each case, accrued interest, if any, from April&nbsp;30, 2020, to the Time of Delivery hereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;Upon the authorization by you of the release of the Securities,
the several Underwriters propose to offer the Securities for sale upon the terms and conditions set forth in the Pricing Prospectus and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;(i) The Securities to be purchased by each Underwriter hereunder will be represented by one or more definitive
global Securities in book-entry form, which will be deposited by or on behalf of the Company with The Depository Trust Company (&#147;<B>DTC</B>&#148;) or its designated custodian. The Company will deliver the Securities to the Representatives, for
the account of each Underwriter, against payment by or on behalf of such Underwriter of the purchase price therefor by wire transfer of Federal <FONT STYLE="white-space:nowrap">(same-day)</FONT> funds to the account specified by the Company to the
Representatives, by causing DTC to credit the Securities to the account of the Representatives at DTC. The Company will cause the certificates representing the Securities to be made available to the Representatives for checking at least twenty-four
hours prior to the Time of Delivery at the office of DTC or its designated custodian (the &#147;<B>Designated Office</B>&#148;). The time and date of such delivery and payment shall be 9:00 a.m., New York City time, on April&nbsp;30, 2020, or such
other time and date as you and the Company may agree upon in writing. Such time and date are herein called the &#147;<B>Time of Delivery</B>.&#148; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;The documents to be delivered at the Time of Delivery by or on behalf of the parties hereto
pursuant to Section&nbsp;8 hereof, including the cross-receipt for the Securities and any additional documents requested by the Underwriters pursuant to Section&nbsp;8(ix) hereof, will be delivered at the offices of Davis Polk&nbsp;&amp; Wardwell
LLP 450 Lexington Avenue, New York, NY 10017 (the &#147;<B>Closing Location</B>&#148;), and the Securities will be delivered at the Designated Office, all at the Time of Delivery. A meeting will be held at the Closing Location at 12:00 p.m., New
York City time, on the New York Business Day next preceding the Time of Delivery, at which meeting the final drafts of the documents to be delivered pursuant to the preceding sentence will be available for review by the parties hereto. For the
purposes of this Section&nbsp;4, &#147;<B>New York Business Day</B>&#148; shall mean each Monday, Tuesday, Wednesday, Thursday and Friday which is not a day on which banking institutions in New York City are generally authorized or obligated by law
or executive order to close. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;The Company agrees with each of the Underwriters: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;To prepare the Prospectus in a form that you have not reasonably disapproved and to file such
Prospectus pursuant to Rule 424(b) under the Act not later than the Commission&#146;s close of business on the second business day following the date of this Agreement; to make no further amendment or any supplement to the Registration Statement,
the Basic Prospectus or the Prospectus prior to the Time of Delivery which shall be reasonably disapproved by you promptly after reasonable notice thereof; to advise you, promptly after it receives notice thereof, of the time when any amendment to
the Registration Statement has been filed or becomes effective or any amendment or supplement to the Prospectus has been filed and to furnish you with copies thereof; to prepare a final term sheet, containing solely a description of the Securities,
in a form approved </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
by you and to file such term sheet pursuant to Rule 433(d) under the Act within the time required by such rule; to file promptly all other material required to be filed by the Company with the
Commission pursuant to Rule 433(d) under the Act; to file promptly all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the
Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) is required in connection with the offering or sale of the Securities; to
advise you, promptly after it receives notice thereof, of the issuance by the Commission of any stop order or of any order preventing or suspending the use of any Preliminary Prospectus or other prospectus in respect of the Securities, of any notice
of objection of the Commission to the use of the Registration Statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Act, of the suspension of the qualification of the Securities for offering or sale in any
jurisdiction, of the initiation or threatening of any proceeding for any such purpose, or of any request by the Commission for the amending or supplementing of the Registration Statement or the Prospectus or for additional information; and, in the
event of the issuance of any stop order or of any order preventing or suspending the use of any Preliminary Prospectus or other prospectus or suspending any such qualification, to promptly use its reasonable best efforts to obtain the withdrawal of
such order; and in the event of any such issuance of a notice of objection, promptly to take such steps including, without limitation, amending the Registration Statement or filing a new registration statement, at its own expense, as may be
necessary to permit offers and sales of the Securities by the Underwriters (references herein to the Registration Statement shall include any such amendment or new registration statement); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;If required by Rule 430B(h) under the Act, to prepare a form of prospectus in a form approved by
you and to file such form of prospectus pursuant to Rule 424(b) under the Act not later than may be required by Rule 424(b) under the Act; and to make no further amendment or supplement to such form of prospectus which shall be reasonably
disapproved by you promptly after reasonable notice thereof; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Promptly from time to time to
take such action as you may reasonably request to qualify the Securities for offering and sale under the securities laws of such jurisdictions as you may request and to comply with such laws so as to permit the continuance of sales and dealings
therein in such jurisdictions for as long as may be necessary to complete the distribution of the Securities, provided that in connection therewith the Company shall not be required to qualify as a foreign corporation or to file a general consent to
service of process in any jurisdiction; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;Prior to 10:00 a.m., New York City time, on the New
York Business Day next succeeding the date of this Agreement and from time to time, to furnish the Underwriters with written and electronic copies of the Prospectus in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
New York City in such quantities as you may reasonably request, and, if the delivery of a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) is required at any
time prior to the expiration of nine months after the time of issue of the Prospectus in connection with the offering or sale of the Securities and if at such time any event shall have occurred as a result of which the Prospectus as then amended or
supplemented would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made when such Prospectus (or in lieu
thereof, the notice referred to in Rule 173(a) under the Act) is delivered, not misleading, or, if for any other reason it shall be necessary during such same period to amend or supplement the Prospectus or to file under the Exchange Act any
document incorporated by reference in the Prospectus in order to comply with the Act, the Exchange Act or the Trust Indenture Act, to notify you and upon your request to file such document and to prepare and furnish without charge to each
Underwriter and to any dealer in securities as many written and electronic copies as you may from time to time reasonably request of an amended Prospectus or a supplement to the Prospectus which will correct such statement or omission or effect such
compliance; and in case any Underwriter is required to deliver a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) in connection with sales of any of the Securities at any time nine months or more after the time of
issue of the Prospectus, upon your request but at the expense of such Underwriter, to prepare and deliver to such Underwriter as many written and electronic copies as you may request of an amended or supplemented Prospectus complying with
Section&nbsp;10(a)(3) of the Act; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;To make generally available to its securityholders as soon as
practicable, but in any event not later than sixteen months after the effective date of the Registration Statement (as defined in Rule 158(c) under the Act), an earnings statement of the Company and its subsidiaries (which need not be audited)
complying with Section&nbsp;11(a) of the Act and the rules and regulations of the Commission thereunder (including, at the option of the Company, Rule 158 under the Act); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;During the period beginning from the date hereof and continuing to and including the later of the
Time of Delivery and such earlier time as you may notify the Company, not to offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise dispose of, except as provided hereunder, any securities of the
Company that are substantially similar to the Securities; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;To pay the required Commission
filing fees relating to the Securities within the time required by Rule 456(b)(1) under the Act without regard to the proviso therein and otherwise in accordance with Rules 456(b) and 457(r) under the Act; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;&nbsp;&nbsp;&nbsp;To use the net proceeds received by it from
the sale of the Securities pursuant to this Agreement in the manner specified in the Pricing Prospectus under the caption &#147;<B>Use of Proceeds</B>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;(A) The Company represents and agrees that, other than the final term sheet prepared and filed
pursuant to Section&nbsp;5(i) hereof, without your prior consent, it has not made and will not make any offer relating to the Securities that would constitute a &#147;<B>free writing prospectus</B>&#148; as defined in Rule 405 under the Act; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) &nbsp;&nbsp;&nbsp;&nbsp;each Underwriter, severally and not jointly, represents and agrees that, without your prior consent
and the consent of the Company, other than one or more term sheets relating to the Securities containing customary information and conveyed to purchasers of Securities, it has not made and will not make any offer relating to the Securities that
would constitute an &#147;<B>issuer free writing prospectus,</B>&#148; as defined in Rule 433 under the Act, or that would otherwise constitute a &#147;<B>free writing prospectus,</B>&#148; as defined in Rule 405, required to be filed with the
Commission; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C)&nbsp;&nbsp;&nbsp;&nbsp;any such free writing prospectus the use of which has been consented to by the
Company and you (including the final term sheet prepared and filed pursuant to Section&nbsp;5(i) hereof) is listed on Schedule II(a) hereto; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;The Company has complied and will comply with the requirements of Rule 433 under the Act applicable
to any Issuer Free Writing Prospectus, including timely filing with the Commission or retention where required and legending; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;The Company agrees that if at any time following issuance of an Issuer Free Writing Prospectus any
event occurred or occurs as a result of which such Issuer Free Writing Prospectus would conflict with the information in the Registration Statement, the Pricing Prospectus or the Prospectus or would include an untrue statement of a material fact or
omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances then prevailing, not misleading, the Company will give prompt notice thereof to you and, if requested by you, will prepare and
furnish without charge to each Underwriter an Issuer Free Writing Prospectus or other document which will correct such conflict, statement or omission; provided, however, that this representation and warranty shall not apply to any statements or
omissions in an Issuer Free Writing Prospectus made in reliance upon and in conformity with information furnished in writing to the Company by an Underwriter through the Representatives expressly for use therein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;The Company covenants and agrees with the several Underwriters that the Company will pay or cause to be paid the
following: (i)&nbsp;the fees, disbursements and expenses of the Company&#146;s counsel and accountants in connection with the registration </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the Securities under the Act and all other expenses in connection with the preparation, printing, reproduction and filing of the Registration Statement, the Basic Prospectus, any Preliminary
Prospectus, any Issuer Free Writing Prospectus and the Prospectus and amendments and supplements thereto and the mailing and delivering of copies thereof to the Underwriters and dealers; (ii)&nbsp;the cost of printing or producing any Agreement
among Underwriters, this Agreement, the Indenture, any Blue Sky memorandum, closing documents (including any compilations thereof) and any other documents in connection with the offering, purchase, sale and delivery of the Securities; (iii)&nbsp;all
expenses in connection with the qualification of the Securities for offering and sale under state securities laws as provided in Section&nbsp;5(iii) hereof, including the fees and disbursements of counsel for the Underwriters in connection with such
qualification and in connection with any Blue Sky memorandum; (iv)&nbsp;fees charged by securities rating services for rating the Securities; (v)&nbsp;the filing fees incident to, and the fees and disbursements of counsel for the Underwriters in
connection with, any required review by the Financial Industry Regulatory Authority, Inc. of the terms of the sale of the Securities, together with the expenses described in clause (iii)&nbsp;above in an amount not to exceed $10,000; (vi) the cost
of preparing the Securities; (vii)&nbsp;the fees and expenses of the Trustee and any agent of the Trustee and the fees and disbursements of counsel for the Trustee in connection with the Indenture and the Securities; and (viii)&nbsp;all other costs
and expenses incident to the performance of its obligations hereunder which are not otherwise specifically provided for in this Section. It is understood, however, that, except as provided in this Section, and Sections 9 and 13 hereof, the
Underwriters will pay all of their own costs and expenses, including the fees of their counsel, transfer taxes on resale of any of the Securities by them and any advertising expenses connected with any offers they may make. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;The obligations of the Underwriters hereunder shall be subject, in their discretion, to the condition that all
representations and warranties and other statements of the Company herein are, at and as of the Time of Delivery, true and correct, the condition that the Company shall have performed all of its obligations hereunder theretofore to be performed, and
the following additional conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;The Prospectus shall have been filed with the Commission
pursuant to Rule 424(b) under the Act within the applicable time period prescribed for such filing by the rules and regulations under the Act and in accordance with Section&nbsp;5(i) hereof; the final term sheet contemplated by Section&nbsp;5(i)
hereof, and any other material required to be filed by the Company pursuant to Rule 433(d) under the Act, shall have been filed with the Commission within the applicable time periods prescribed for such filings by Rule 433; no stop order suspending
the effectiveness of the Registration Statement or any part thereof shall have been issued and no proceeding for that purpose shall have been initiated or threatened by the Commission and no notice of objection of the Commission to the use of the
Registration Statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Act shall have been received; no stop order suspending or preventing the use of the Prospectus or any Issuer Free Writing Prospectus shall have been
initiated or threatened by the Commission; and all requests for additional information on the part of the Commission shall have been complied with to your reasonable satisfaction; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Davis Polk&nbsp;&amp; Wardwell LLP, counsel for
the Underwriters, shall have furnished to you such written opinion or opinions, dated the date of the Time of Delivery, in form and substance satisfactory to you, and such counsel shall have received such papers and information as they may
reasonably request to enable them to pass upon such matters; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Foley Hoag LLP, counsel for the
Company, shall have furnished to you its written opinion or opinions, dated the date of the Time of Delivery, in form and substance reasonably satisfactory to you; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;On the date of the Prospectus at a time prior to the execution of this Agreement, at 9:30 a.m., New
York City time, on the effective date of any post-effective amendment to the Registration Statement filed subsequent to the date of this Agreement and also at the Time of Delivery, PricewaterhouseCoopers LLP shall have furnished to you a letter or
letters, dated the respective dates of delivery thereof, in form and substance reasonably satisfactory to you, containing statements and information of the type ordinarily included in accountants&#146; &#147;<B>comfort letters</B>&#148; to
underwriters with respect to financial statements and certain financial information contained in the Registration Statement, Pricing Prospectus and the Prospectus. The letter to be delivered on the effective date of any post-effective amendment to
the Registration Statement and as of the Time of Delivery shall reaffirm the statements made in the letter furnished on the date of the Prospectus, except that statements made therein as of a specified date subsequent to the date of the latest
balance sheet and income statement of the Company shall be as of a date not more than three business days prior to the date of such post-effective amendment or Time of Delivery, as applicable; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;(i) Neither the Company nor any of its subsidiaries shall have sustained since the date of the
latest audited financial statements included or incorporated by reference in the Pricing Prospectus any loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor
dispute or court or governmental action, order or decree, otherwise than as set forth or contemplated in the Pricing Prospectus, and (ii)&nbsp;since the respective dates as of which information is given in the Pricing Prospectus there shall not have
been any change in the capital stock or long-term debt of the Company or any of its subsidiaries or any change, or any development involving a prospective change, in or affecting the business, management, financial position, stockholders&#146;
equity or results of operations of the Company and its subsidiaries (other than changes due to grants, exercises, and terminations under Company incentive plans referred to in the Pricing Prospectus and in the documents incorporated by reference
therein and other publicly announced share repurchase programs), otherwise than as set forth or contemplated in the Pricing Prospectus, the effect of which, in any such case described in clause (i)&nbsp;or (ii), is in your judgment so material and
adverse as to make it impracticable or inadvisable to proceed with the public offering or the delivery of the Securities on the terms and in the manner contemplated in the Prospectus; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vi)&nbsp;&nbsp;&nbsp;&nbsp;On or after the Applicable Time (i)&nbsp;no
downgrading shall have occurred in the rating accorded the Company&#146;s debt securities by any &#147;<B>nationally recognized statistical rating organization</B>&#148; (as defined in Section&nbsp;3(a)(62) of the Exchange Act), and (ii)&nbsp;no
such organization shall have publicly announced that it has under surveillance or review, with possible negative implications, its rating of any of the Company&#146;s debt securities; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vii)&nbsp;&nbsp;&nbsp;&nbsp;On or after the Applicable Time there shall not have occurred any of the following: (i)&nbsp;a
suspension or material limitation in trading in securities generally on the New York Stock Exchange or the Nasdaq Global Select Market; (ii)&nbsp;a suspension or material limitation in trading in the Company&#146;s securities on the Nasdaq Global
Select Market; (iii)&nbsp;a general moratorium on commercial banking activities declared by either Federal or New York State authorities or a material disruption in commercial banking or securities settlement or clearance services in the United
States; (iv)&nbsp;the outbreak or escalation of hostilities involving the United States or the declaration by the United States of a national emergency or war or (v)&nbsp;the occurrence of any other calamity or crisis or any change in financial,
political or economic conditions in the United States or elsewhere, if the effect of any such event specified in clause (iv)&nbsp;or (v) in your judgment makes it impracticable or inadvisable to proceed with the public offering or the delivery of
the Securities on the terms and in the manner contemplated in the Prospectus; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(viii)&nbsp;&nbsp;&nbsp;&nbsp;The Company
shall have complied with the provisions of Section&nbsp;5(iv) hereof with respect to the furnishing of prospectuses on the New York Business Day next succeeding the date of this Agreement; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ix)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall have furnished or caused to be furnished to you at the Time of Delivery
certificates of officers of the Company satisfactory to you as to the accuracy of the representations and warranties of the Company herein at and as of such time, as to the performance by the Company of all of its obligations hereunder to be
performed at or prior to such time, as to the matters set forth in subsections (i)&nbsp;and (v) of this Section and as to such other matters as you may reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The Company will indemnify and hold harmless each Underwriter against any losses, claims, damages or
liabilities, joint or several, to which such Underwriter may become subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or
alleged untrue statement of a material fact contained in the Registration Statement, the Basic Prospectus, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, any Issuer Free Writing
Prospectus or any &#147;<B>issuer information</B>&#148; filed or required to be filed pursuant to Rule 433(d) under the Act, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated
therein or necessary to make the statements therein not misleading, and will reimburse each Underwriter for any reasonable legal or other expenses reasonably incurred by such Underwriter in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
connection with investigating or defending any such action or claim as such expenses are incurred; provided, however, that the Company shall not be liable in any such case to the extent that any
such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in the Registration Statement, the Basic Prospectus, any Preliminary Prospectus, the Pricing
Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, in reliance upon and in conformity with written information furnished to the Company by any Underwriter through the Representatives
expressly for use therein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;Each Underwriter will, severally and not jointly, indemnify and
hold harmless the Company against any losses, claims, damages or liabilities to which the Company may become subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or
are based upon an untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, the Basic Prospectus, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement
thereto, or any Issuer Free Writing Prospectus, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in each
case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, the Basic Prospectus, any Preliminary Prospectus, the Pricing Prospectus or
the Prospectus or any such amendment or supplement thereto, or any Issuer Free Writing Prospectus, in reliance upon and in conformity with written information furnished to the Company by such Underwriter through the Representatives expressly for use
therein and will reimburse the Company for any reasonable legal or other expenses reasonably incurred by the Company in connection with investigating or defending any such action or claim as such expenses are incurred. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;Promptly after receipt by an indemnified party under subsection (i)&nbsp;or (ii) above of notice
of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying party in writing of the commencement thereof; but the omission
so to notify the indemnifying party shall not relieve it from any liability which it may have to any indemnified party otherwise than under such subsection. The indemnifying party shall be entitled to participate therein, and, to the extent that it
shall wish, jointly with any other indemnifying party under the same subsection, to assume the defense thereof and appoint counsel of the indemnifying party&#146;s choice at the indemnifying party&#146;s expense to represent the indemnified party in
any action for which indemnification is or may be sought (in which case the indemnifying party shall not be responsible for the fees and expenses of any separate counsel for the indemnified party or parties or any other expenses thereafter incurred
by the indemnified party in connection with the defense thereof, other than reasonable costs of investigation and except as set forth below); provided, however, that such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
counsel shall be reasonably satisfactory to the indemnified party. Notwithstanding the indemnifying party&#146;s election to appoint counsel to represent the indemnified party in an action, the
indemnified party shall have the right to employ separate counsel (including local counsel), and the indemnifying party shall bear the reasonable fees, costs and expenses of such separate counsel if (A)&nbsp;the use of counsel chosen by the
indemnifying party to represent the indemnified party would present such counsel with a conflict of interest, (B)&nbsp;the actual or potential defendants in, or targets of, any such action include both the indemnified party and the indemnifying
party and the indemnified party shall have reasonably concluded that there may be legal defenses available to it and/or other indemnified parties which are different from or additional to those available to the indemnifying party, (C)&nbsp;the
indemnifying party has not employed counsel reasonably satisfactory to the indemnified party to represent the indemnified party within a reasonable time after notice of the institution of such action or (D)&nbsp;the indemnifying party shall
authorize the indemnified party in writing to employ separate counsel at the expense of the indemnifying party; provided, however, that in no event shall the indemnifying parties be liable for fees and expenses of more than one counsel (in addition
to one local counsel) separate from their own counsel for all indemnified parties in connection with any one action or separate but similar or related actions in the same jurisdiction arising out of the same general allegations or
circumstances.&nbsp;No indemnifying party shall, without the written consent of the indemnified party, effect the settlement or compromise of, or consent to the entry of any judgment with respect to, any pending or threatened action or claim in
respect of which indemnification or contribution may be sought hereunder (whether or not the indemnified party is an actual party to such action or claim) unless such settlement, compromise or judgment (A)&nbsp;includes an unconditional release of
the indemnified party from all liability arising out of such action or claim and (B)&nbsp;does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any indemnified party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv)&nbsp;&nbsp;&nbsp;&nbsp;If the indemnification provided for in this Section&nbsp;9 is unavailable to or insufficient to
hold harmless an indemnified party under subsection (i)&nbsp;or (ii) above in respect of any losses, claims, damages or liabilities (or actions in respect thereof) referred to therein, then each indemnifying party shall contribute to the amount paid
or payable by such indemnified party as a result of such losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the
Underwriters on the other from the offering of the Securities. If, however, the allocation provided by the immediately preceding sentence is not permitted by applicable law, then each indemnifying party shall contribute to such amount paid or
payable by such indemnified party in such proportion as is appropriate to reflect not only such relative benefits but also the relative fault of the Company on the one hand and the Underwriters on the other in connection with the statements or
omissions which resulted in such losses, claims, damages or liabilities (or actions in respect thereof), as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on
the other shall be deemed to be in the same proportion as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the total net proceeds from the offering (before deducting expenses) received by the Company bear to the total underwriting discounts and commissions received by the Underwriters, in each case as
set forth in the table on the cover page of the Prospectus. The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a
material fact relates to information supplied by the Company on the one hand or the Underwriters on the other and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.
The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this subsection (iv)&nbsp;were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by
any other method of allocation which does not take account of the equitable considerations referred to above in this subsection (iv). The amount paid or payable by an indemnified party as a result of the losses, claims, damages or liabilities (or
actions in respect thereof) referred to above in this subsection (iv)&nbsp;shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim.
Notwithstanding the provisions of this subsection (iv), no Underwriter shall be required to contribute any amount in excess of the amount by which the total price at which the Securities underwritten by it and distributed to the public were offered
to the public exceeds the amount of any damages which such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within
the meaning of Section&nbsp;11(f) of the Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146; obligations in this subsection (iv)&nbsp;to contribute are several in
proportion to their respective underwriting obligations and not joint. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;The obligations of the
Company under this Section&nbsp;9 shall be in addition to any liability which the Company may otherwise have and shall extend, upon the same terms and conditions, to each person, if any, who controls any Underwriter within the meaning of the Act and
each affiliate, selling agent, officer and director of any Underwriter; and the obligations of the Underwriters under this Section&nbsp;9 shall be in addition to any liability which the respective Underwriters may otherwise have and shall extend,
upon the same terms and conditions, to each officer and director of the Company and to each person, if any, who controls the Company within the meaning of the Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;(i) If any Underwriter shall default in its obligation to purchase the Securities, which it has agreed to purchase
hereunder, you may in your discretion arrange for you or another party or other parties to purchase such Securities on the terms contained herein. If within <FONT STYLE="white-space:nowrap">thirty-six</FONT> hours after such default by any
Underwriter you do not arrange for the purchase of such Securities, then the Company shall be entitled to a further period of <FONT STYLE="white-space:nowrap">thirty-six</FONT> hours within which to procure another party or other parties
satisfactory to you to purchase such Securities on such terms. In the event that, within the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
respective prescribed periods, you notify the Company that you have so arranged for the purchase of such Securities, or the Company notifies you that it has so arranged for the purchase of such
Securities, you or the Company shall have the right to postpone the Time of Delivery for a period of not more than seven days, in order to effect whatever changes may thereby be made necessary in the Registration Statement or the Prospectus, or in
any other documents or arrangements, and the Company agrees to file promptly any amendments or supplements to the Registration Statement or the Prospectus which in your opinion may thereby be made necessary. The term &#147;<B>Underwriter</B>&#148;
as used in this Agreement shall include any person substituted under this Section with like effect as if such person had originally been a party to this Agreement with respect to such Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;If, after giving effect to any arrangements for the purchase of the Securities of a defaulting
Underwriter or Underwriters by you and the Company as provided in subsection (i)&nbsp;above, the aggregate principal amount of such Securities which remains unpurchased does not exceed one eleventh of the aggregate principal amount of all the
Securities, then the Company shall have the right to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter to purchase the principal amount of Securities which such Underwriter agreed to purchase hereunder and, in addition,
to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter to purchase its pro rata share (based on the principal amount of Securities which such Underwriter agreed to purchase hereunder) of the Securities of such defaulting
Underwriter or Underwriters for which such arrangements have not been made; but nothing herein shall relieve a defaulting Underwriter from liability for its default. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;If, after giving effect to any arrangements for the purchase of the Securities of a defaulting
Underwriter or Underwriters by you and the Company as provided in subsection (i)&nbsp;above, the aggregate principal amount of Securities which remains unpurchased exceeds one eleventh of the aggregate principal amount of all the Securities, or if
the Company shall not exercise the right described in subsection (ii)&nbsp;above to require <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters to purchase Securities of a defaulting Underwriter or Underwriters, then this Agreement
shall thereupon terminate, without liability on the part of any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter or the Company, except for the expenses to be borne by the Company and the Underwriters as provided in Section&nbsp;7
hereof and the indemnity and contribution agreements in Section&nbsp;9 hereof; but nothing herein shall relieve a defaulting Underwriter from liability for its default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) In the event that any Underwriter that is a Covered Entity (as defined below) becomes subject to a
proceeding under a U.S. Special Resolution Regime (as defined below), the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be
effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate (as defined
below) of such Underwriter becomes subject to a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
proceeding under a U.S. Special Resolution Regime, Default Rights (as defined below) under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no
greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Section&nbsp;11: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>BHC Act Affiliate</B>&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be interpreted in accordance
with, 12 U.S.C. &#167; 1841(k). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Covered Entity</B>&#148; means any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance
with, 12 C.F.R. &#167; 252.82(b); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a &#147;covered bank&#148; as that term is defined in,
and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b); or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii)&nbsp;&nbsp;&nbsp;&nbsp;a &#147;covered FSI&#148; as
that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 382.2(b). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>Default Right</B>&#148; has the meaning
assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &#167;&#167; 252.81, 47.2 or 382.1, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<B>U.S. Special Resolution Regime</B>&#148; means each of (i)&nbsp;the Federal Deposit Insurance Act and the regulations promulgated
thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;The respective indemnities, agreements, representations, warranties and other statements of the Company and the
several Underwriters, as set forth in this Agreement or made by or on behalf of them, respectively, pursuant to this Agreement, shall remain in full force and effect, regardless of any investigation (or any statement as to the results thereof) made
by or on behalf of any Underwriter or any controlling person of any Underwriter, or the Company, or any officer or director or controlling person of the Company, and shall survive delivery of and payment for the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;If this Agreement shall be terminated pursuant to Section&nbsp;10 hereof, the Company shall not then be under any
liability to any Underwriter except as provided in Sections 7 and 9 hereof; but, if the Securities are not delivered by or on behalf of the Company as provided herein other than as a result of a failure of the conditions set forth in paragraph
(vii)&nbsp;of Section&nbsp;8, the Company will reimburse the Underwriters through you for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses approved in writing by you, including fees and
disbursements of counsel, reasonably incurred by the Underwriters in making preparations for the purchase, sale and delivery of the Securities, but the Company shall then be under no further liability to any Underwriter except as provided in
Sections 7 and 9 hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&nbsp;&nbsp;&nbsp;&nbsp;In all dealings hereunder, you shall act on behalf of each of the
Underwriters, and the parties hereto shall be entitled to act and rely upon any statement, request, notice or agreement on behalf of any Underwriter made or given by you jointly or on behalf of you as the Representatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All statements, requests, notices and agreements hereunder shall be in writing, and if to the Underwriters shall be delivered or sent by mail
or facsimile transmission to you as the Representatives in care of: (i)&nbsp;Goldman Sachs&nbsp;&amp; Co. LLC, 200 West Street, New York, New York 10282-2198, Attention: Registration Department; (ii)&nbsp;BofA Securities, Inc., 50 Rockefeller Plaza,
NY1 050 12 01, New York, NY 10020, Attention: High Grade Debt Capital Markets Transaction Management/Legal, Facsimile: (212) <FONT STYLE="white-space:nowrap">901-7881;</FONT> and (iii)&nbsp;J.P. Morgan Securities LLC, 383 Madison Avenue, New York,
NY 10179, Attn: Investment Grade Syndicate Desk, Fax: (212) <FONT STYLE="white-space:nowrap">834-6081;</FONT> and if to the Company shall be delivered or sent by mail or facsimile transmission to the address of the Company set forth in the
Registration Statement, Attention: Secretary; provided, however, that any notice to an Underwriter pursuant to Section&nbsp;9(iii) hereof shall be delivered or sent by mail or facsimile transmission to such Underwriter at its address set forth in
its Underwriters&#146; Questionnaire, which address will be supplied to the Company by you upon request. Any such statements, requests, notices or agreements shall take effect upon receipt thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. <FONT STYLE="white-space:nowrap">107-56</FONT> (signed into
law October&nbsp;26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company, which information may include the name and address of their respective clients, as
well as other information that will allow the underwriters to properly identify their respective clients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&nbsp;&nbsp;&nbsp;&nbsp;This
Agreement shall be binding upon, and inure solely to the benefit of, the Underwriters, the Company and, to the extent provided in Sections 9 and 12 hereof, the officers and directors of the Company and each person who controls the Company or any
Underwriter, and their respective heirs, executors, administrators, successors and assigns, and no other person shall acquire or have any right under or by virtue of this Agreement. No purchaser of any of the Securities from any Underwriter shall be
deemed a successor or assign by reason merely of such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&nbsp;&nbsp;&nbsp;&nbsp;Time shall be of the essence of this
Agreement. As used herein, the term &#147;<B>business day</B>&#148; shall mean any day when the Commission&#146;s office in Washington, D.C. is open for business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">17.&nbsp;&nbsp;&nbsp;&nbsp;The Company acknowledges and agrees that (i)&nbsp;the purchase and sale of the Securities pursuant to this
Agreement is an <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> commercial transaction between the Company, on the one hand, and the several Underwriters, on the other, (ii)&nbsp;in connection therewith and with the process leading to such
transaction each Underwriter is acting solely as a principal and not the agent or fiduciary of the Company, (iii)&nbsp;no Underwriter has assumed an advisory or fiduciary responsibility in favor of the Company with respect to the offering
contemplated hereby or the process leading thereto </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(irrespective of whether such Underwriter has advised or is currently advising the Company on other matters) or any other obligation to the Company except the obligations expressly set forth in
this Agreement, (iv)&nbsp;the Underwriters and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company, (v)&nbsp;the Underwriters have not provided any legal,
accounting, financial, regulatory or tax advice with respect to the offering of the Securities and (vi)&nbsp;the Company has consulted its own legal, accounting, financial, regulatory and tax advisors to the extent it deemed appropriate. The Company
agrees that it will not claim that the Underwriters, or any of them, has rendered advisory services of any nature or respect, or owes a fiduciary or similar duty to the Company, in connection with such transaction or the process leading thereto.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">18.&nbsp;&nbsp;&nbsp;&nbsp;THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS AGREEMENT SHALL BE
GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">19.&nbsp;&nbsp;&nbsp;&nbsp;Each of the Company and the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable
law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">20.&nbsp;&nbsp;&nbsp;&nbsp;This Agreement may be executed by any one or more of the parties hereto in any number of counterparts, each of
which shall be deemed to be an original, but all such respective counterparts shall together constitute one and the same instrument. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or other electronic
transmission shall be effective as delivery of a manually executed counterpart thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">21.&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything herein to the contrary, the Company is authorized to disclose to any persons the U.S. federal and state income tax treatment and tax structure of the potential transaction and all materials of any kind (including tax opinions and other tax
analyses) provided to the Company relating to that treatment and structure, without the Underwriters, imposing any limitation of any kind. However, any information relating to the tax treatment and tax structure shall remain confidential (and the
foregoing sentence shall not apply) to the extent necessary to enable any person to comply with securities laws. For this purpose, &#147;<B>tax structure</B>&#148; is limited to any facts that may be relevant to that treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">22.&nbsp;&nbsp;&nbsp;&nbsp;This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written
or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement shall not become effective until the execution of this Agreement by the parties hereto. This Agreement may not
be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the parties hereto acknowledges that it is a sophisticated business person who was
adequately represented by counsel during negotiations regarding the provisions hereof, including, without limitation, the indemnification and contribution provisions of Section&nbsp;9, and is fully informed regarding said provisions. Each of the
parties hereto further acknowledges that the provisions of Section&nbsp;9 hereto fairly allocate the risks in light of the ability of the parties to investigate the Company, its affairs and its business in order to assure that adequate disclosure
has been made in the Registration Statement, the Pricing Disclosure Package and the Prospectus (and any amendments and supplements thereto), as required by the Act and the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, please sign and
return to the Company a counterpart hereof, whereupon this instrument, along with all counterparts, will become a binding agreement between the Underwriters and the Company in accordance with its terms. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Biogen Inc.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Michael Dambach</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name: Michael Dambach</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:&nbsp;&nbsp;&nbsp;Vice President, Treasurer</P></TD></TR>
</TABLE> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[ Signature Page to the Underwriting Agreement ] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accepted as of the date hereof: <BR></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Adam T. Greene</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name: Adam T. Greene</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title: Managing Director</P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Douglas A Muller</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name: Douglas A Muller</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title: Managing Director</P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">/s/ Som Bhattacharyya</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name: Som Bhattacharyya</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title: Executive Director</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For themselves and as Representatives of the other Underwriters. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:96pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:96pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:96pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:96pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[ Signature Page to the Underwriting Agreement ] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE I </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal Amount of 2030<BR>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Principal Amount of 2050<BR>Notes</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 360,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 360,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BofA Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citigroup Global Markets Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deutsche Bank Securities Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mizuho Securities USA LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">U.S. Bancorp Investments, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Wells Fargo Securities, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Academy Securities, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loop Capital Markets LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;1,500,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;1,500,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE II </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Issuer Free Writing Prospectuses not included in the Pricing Disclosure Package: </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Electronic roadshow posted as of April&nbsp;24, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Additional Documents Incorporated by Reference: None. </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.2
<SEQUENCE>3
<FILENAME>d857739dex42.htm
<DESCRIPTION>EX-4.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit 4.2 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>BIOGEN INC., </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>as Issuer </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>U.S. Bank National Association, </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>as Trustee </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Second
Supplemental Indenture </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated as of April&nbsp;30, 2020 </B></P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex4_1toc857739_1">ARTICLE I DEFINITIONS SECTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex4_1toc857739_2">Section&nbsp;1.1.&nbsp;&nbsp;&nbsp;&nbsp;
<U>Certain Terms Defined in the Indenture</U></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex4_1toc857739_3">Section&nbsp;1.2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex4_1toc857739_4">ARTICLE II FORM AND TERMS OF THE NOTES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex4_1toc857739_5">Section&nbsp;2.1.&nbsp;&nbsp;&nbsp;&nbsp;Form and
Dating</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex4_1toc857739_6">Section&nbsp;2.2.&nbsp;&nbsp;&nbsp;&nbsp;Terms of the
Notes</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex4_1toc857739_7">Section&nbsp;2.3.&nbsp;&nbsp;&nbsp;&nbsp;Optional
Redemption</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex4_1toc857739_8">Section&nbsp;2.4.&nbsp;&nbsp;&nbsp;&nbsp;
Repurchase of Notes Upon a Change of Control</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex4_1toc857739_9">Section&nbsp;2.5.&nbsp;&nbsp;&nbsp;&nbsp;Limitation on
Liens</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex4_1toc857739_10">Section&nbsp;2.6.&nbsp;&nbsp;&nbsp;&nbsp;
Limitation on Sale and Leaseback Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex4_1toc857739_11">Section&nbsp;2.7.&nbsp;&nbsp;&nbsp;&nbsp;
Exempted Liens and Sale and Leaseback Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex4_1toc857739_12">Section&nbsp;2.8.&nbsp;&nbsp;&nbsp;&nbsp;Other
Amendments</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex4_1toc857739_13">ARTICLE III MISCELLANEOUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex4_1toc857739_14">Section&nbsp;3.1.&nbsp;&nbsp;&nbsp;&nbsp;
Trust Indenture Act Controls</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex4_1toc857739_15">Section&nbsp;3.2.&nbsp;&nbsp;&nbsp;&nbsp;Governing
Law</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex4_1toc857739_16">Section&nbsp;3.3.&nbsp;&nbsp;&nbsp;&nbsp;Multiple
Counterparts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex4_1toc857739_17">Section&nbsp;3.4.&nbsp;&nbsp;&nbsp;&nbsp;Severability</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex4_1toc857739_18">Section&nbsp;3.5.&nbsp;&nbsp;&nbsp;&nbsp;Ratification</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex4_1toc857739_19">Section&nbsp;3.6.&nbsp;&nbsp;&nbsp;&nbsp;Effectiveness</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex4_1toc857739_20">Section&nbsp;3.7.&nbsp;&nbsp;&nbsp;&nbsp;Notices, Approvals,
etc</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex4_1toc857739_21">EXHIBIT A Form of 2.250% Senior Note due 2030</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">A-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#ex4_1toc857739_22">EXHIBIT B Form of 3.150% Senior Note due 2050</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">B-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECOND SUPPLEMENTAL INDENTURE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">SUPPLEMENTAL INDENTURE (this &#147;Second Supplemental Indenture&#148;), dated as of April&nbsp;30, 2020, between BIOGEN INC., a Delaware
corporation (the &#147;Company&#148;), and U.S. Bank National Association, a national association, as Trustee (the &#147;Trustee&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">RECITALS OF THE COMPANY </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company and the Trustee executed and delivered an Indenture, dated as of September&nbsp;15, 2015 (the &#147;Indenture&#148;), to
provide for the issuance by the Company from time to time of Securities to be issued in one or more Series as provided in the Indenture; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the issuance and sale of $1,500,000,000 aggregate principal amount of a new Series of the Securities of the Company designated as its
2.250% Senior Notes due May&nbsp;1, 2030 (the &#147;Notes due 2030&#148;) and $1,500,000,000 aggregate principal amount of a new Series of the Securities of the Company designated as its 3.150% Senior Notes due May&nbsp;1, 2050 (the &#147;Notes due
2050&#148; and, together with the Notes due 2030, the &#147;Notes&#148;) have been authorized by resolutions adopted by the Board of Directors of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to issue and sell $3,000,000,000 aggregate principal amount of the Notes on the date hereof; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, Sections 2.2 and 8.1 of the Indenture provide that the Company, when authorized by a Board Resolution, and the Trustee may amend or
supplement the Indenture to provide for the issuance of and to establish the form or terms and conditions of Securities of any Series as permitted by the Indenture; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Company desires to establish the form, terms and conditions of the Notes; and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, all things necessary to make this Second Supplemental Indenture a valid supplement to the Indenture according to its terms and the
terms of the Indenture have been done; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, for and in consideration of the premises stated herein and the purchase of the
Notes by the Holders thereof, the parties hereto hereby enter into this Second Supplemental Indenture, for the equal and proportionate benefit of all Holders of the Notes, as follows: </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex4_1toc857739_1"></A>ARTICLE I </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DEFINITIONS SECTION </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="ex4_1toc857739_2">
</A>Section&nbsp;1.1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain Terms Defined in the Indenture</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Second Supplemental
Indenture, all capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Indenture, as amended hereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="ex4_1toc857739_3"></A>Section&nbsp;1.2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the benefit of the Holders of the Notes, Section&nbsp;1.1 of the Indenture shall be amended by adding the following new definitions: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Attributable Debt&#148; means, with respect to a Sale and Leaseback Transaction, an amount equal to the lesser of (1)&nbsp;the fair
market value of the property (as determined in good faith by the Company&#146;s board of directors); and (2)&nbsp;the present value of the total net amount of rent payments to be made under the lease during its remaining term, discounted at the rate
of interest set forth or implicit in the terms of the lease, compounded semi-annually. The calculation of the present value of the total net amount of rent payments is subject to adjustments specified in the indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Change of Control&#148; means the occurrence of any of the following: (1)&nbsp;the consummation of any transaction (including, without
limitation, any merger or consolidation) the result of which is that any &#147;person&#148; (as such term is used in Section&nbsp;13(d) of the Exchange Act) (other than the Company or one of its Subsidiaries) becomes the beneficial owner (as defined
in Rules <FONT STYLE="white-space:nowrap">13d-3</FONT> and <FONT STYLE="white-space:nowrap">13d-5</FONT> under the Exchange Act), directly or indirectly, of more than 50% of the Voting Stock of the Company or other Voting Stock into which the Voting
Stock of the Company is reclassified, consolidated, exchanged or changed, measured by voting power rather than number of shares; <U>provided</U>, <U>however</U>, that a Person shall not be deemed beneficial owner of, or to own beneficially,
(A)&nbsp;any Securities tendered pursuant to a tender or exchange offer made by or on behalf of such Person or any of such Person&#146;s Affiliates until such tendered Securities are accepted for purchase or exchange thereunder, or (B)&nbsp;any
Securities if such beneficial ownership (i)&nbsp;arises solely as a result of a revocable proxy delivered in response to a proxy or consent solicitation made pursuant to the applicable rules and regulations under the Exchange Act, and (ii)&nbsp;is
not also then reportable on Schedule&nbsp;13D (or any successor schedule) under the Exchange Act; (2)&nbsp;the direct or indirect sale, transfer, conveyance or other disposition (other than by way of merger or consolidation), in one or more series
of related transactions, of all or substantially all of the assets of the Company and the assets of its Subsidiaries, taken as a whole, to one or more &#147;persons&#148; (as such term is used in Section&nbsp;13(d) of the Exchange Act) (other than
to the Company or one of its Subsidiaries) (a &#147;Transferee&#148;), <U>provided</U>, <U>however</U>, that none of the circumstances in this clause&nbsp;(2) will be a Change of Control if the Persons that beneficially own the Company&#146;s Voting
Stock immediately prior to the transaction own, directly or indirectly, shares representing a majority of the total Voting Stock as measured by voting power rather than number of shares of the Transferee; (3)&nbsp;the Company consolidates with, or
merges with or into, any &#147;person&#148; (as such term is used in Section&nbsp;13(d) of the Exchange Act) or any such Person consolidates with, or merges with or into, the Company, in either case, pursuant to a transaction in which any of the
Company&#146;s outstanding Voting Stock or the Voting Stock of such other Person is converted into or exchanged for cash, securities or other property, other than pursuant to a transaction in which shares of the Company&#146;s Voting Stock
outstanding immediately prior to the transaction constitute, or are converted into or exchanged for, a majority of the Voting Stock of the surviving Person immediately after giving effect to such transaction; or (4)&nbsp;the adoption of a plan
relating to the Company&#146;s liquidation or dissolution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Change of Control Triggering Event&#148; means the occurrence of both a
Change of Control and a Rating Event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Comparable Treasury Issue&#148; means the U.S. Treasury security or securities
selected by an Independent Investment Banker as having an actual or interpolated maturity comparable to the remaining term of the Notes of the applicable Series (&#147;Remaining Life&#148;) to be redeemed that would be utilized, at the time of
selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of a comparable maturity to the remaining term of such Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Comparable Treasury Price&#148; means, with respect to any Notes of a Series on any Redemption Date, (A)&nbsp;the average of the
Reference Treasury Dealer Quotations for such Redemption Date, after excluding the highest and lowest such Reference Treasury Dealer Quotations, or (B)&nbsp;if the Independent Investment Banker obtains fewer than four such Reference Treasury Dealer
Quotations, the average of all such quotations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Consolidated Total Assets&#148; means, with respect to any Person as of any date,
the amount of total assets as shown on the consolidated balance sheet of such Person for the most recent fiscal quarter for which financial statements have been filed with the Securities and Exchange Commission, prepared in accordance with
accounting principles generally accepted in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Fitch&#148; means Fitch Inc., or any successor thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Global Notes&#148; means, individually and collectively, each of the Notes in the form of Global Securities issued to DTC or its
nominee, substantially in the form of Exhibits A, B and C. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Independent Investment Banker&#148; means one of the Reference Treasury
Dealers appointed by the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Investment Grade Rating&#148; means a rating equal to or higher than Baa3 (or the equivalent) by
Moody&#146;s and <FONT STYLE="white-space:nowrap">BBB-</FONT> (or the equivalent) by S&amp;P or Fitch, and the equivalent investment grade credit rating from any additional rating agency or Rating Agencies selected by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Lien&#148; means any pledge, mortgage, lien, encumbrance or other security interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Moody&#146;s&#148; means Moody&#146;s Investors Service, Inc. or any successor thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Par Call Date&#148; means (1)&nbsp;with respect to the Notes due 2030, three months prior to the maturity date of the Notes due 2030 and
(2)&nbsp;with respect to the Notes due 2050, six months prior to the maturity date of the Notes due 2050. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Principal Property&#148;
means (1)&nbsp;any manufacturing facility, together with the land upon which it is erected and fixtures comprising a part thereof, owned or leased by the Company or any Subsidiary and located within the continental United States and having a net
book value which, on the date the determination as to whether a property is a Principal Property is being made, exceeds 1% of the Company&#146;s Consolidated Total Assets other than any such facility or a portion thereof which the Company&#146;s
board of directors determines in good faith, at any time on or prior to such date, is not of material importance to the total business conducted, or assets owned, by the Company and its Subsidiaries as an entirety or (2)&nbsp;any shares of stock or
Indebtedness of any Subsidiary owning a Principal Property. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Rating Agencies&#148; means (1)&nbsp;each of Fitch, Moody&#146;s and S&amp;P and
(2)&nbsp;if any of Fitch, Moody&#146;s and S&amp;P ceases to rate the Notes or fails to make a rating of the Notes publicly available for reasons outside of the control of the Company, a &#147;nationally recognized statistical rating
organization&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">15c3-1(c)(2)(vi)(F)</FONT> under the Exchange Act selected by the Company (as certified by a resolution of the Board of Directors of the Company) and which is reasonably
acceptable to the Trustee as a replacement agency for Fitch, Moody&#146;s or S&amp;P, or all of them, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Rating
Event&#148; means with respect to any Series of Notes, the rating on such Notes is lowered by at least two of the three Rating Agencies and such Notes are rated below an Investment Grade Rating by at least two of the three Rating Agencies, on any
day during the period commencing on the earlier of the date of the first public notice of the occurrence of a Change of Control or the Company&#146;s intention to effect a Change of Control and ending 60 days following consummation of such Change of
Control (which period will be extended so long as the rating of the applicable Series of Notes is under publicly announced consideration for a possible downgrade by any of the Rating Agencies). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Reference Treasury Dealer&#148; means each of Goldman Sachs&nbsp;&amp; Co. LLC, BofA Securities, Inc. and J.P. Morgan Securities LLC, or
their respective affiliates, which are primary U.S. Government securities dealers in The City of New York, and their respective successors plus three other primary U.S. Government securities dealers in The City of New York selected by the Company;
<U>provided</U>, <U>however</U>, that if any of the foregoing or their affiliates shall cease to be a primary U.S. Government securities dealer in The City of New York (a &#147;Primary Treasury Dealer&#148;), the Company will substitute therefor
another Primary Treasury Dealer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Reference Treasury Dealer Quotations&#148; means, with respect to each Reference Treasury Dealer
and any Redemption Date, the average, as determined by the Independent Investment Banker, of the bid and asked prices for the applicable Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to
the Trustee by the Reference Treasury Dealers at 3:30 p.m. New York time on the third Business Day preceding such Redemption Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Sale and Leaseback Transaction&#148; means any arrangement with any Person providing for the leasing by the Company or any Subsidiary of
the Company of any property that has been or is to be sold or transferred by the Company or such Subsidiary, as the case may be, to such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Subsidiary&#148; of any Person means (1)&nbsp;a corporation, a majority of the outstanding voting stock of which is, at the time,
directly or indirectly, owned by such Person by one or more Subsidiaries of such Person, or by such Person and one or more Subsidiaries thereof or (2)&nbsp;any other Person (other than a corporation), including, without limitation, a partnership or
joint venture, in which such Person, one or more Subsidiaries thereof or such Person and one or more Subsidiaries thereof, directly or indirectly, at the date of determination thereof, has at least majority ownership interest entitled to vote in the
election of directors, managers or trustees thereof (or other Person performing similar functions). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;S&amp;P&#148; means Standard&nbsp;&amp; Poor&#146;s Ratings Services, a
Standard&nbsp;&amp; Poor&#146;s Financial Services LLC business, or any successor thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Treasury Rate&#148; means, with respect
to any Redemption Date: (1)&nbsp;the rate per annum equal to the yield, under the heading which represents the average for the immediately preceding week, appearing in the most recently published statistical release designated &#147;H.15(519)&#148;
or any successor publication which is published weekly by the Board of Governors of the Federal Reserve System and which establishes yields on actively traded U.S. Treasury securities adjusted to constant maturity under the caption &#147;Treasury
Constant Maturities&#148; for the maturity corresponding to the Comparable Treasury Issue; <U>provided</U> that, if no maturity is within three months before or after the Remaining Life of the Notes to be redeemed, yields for the two published
maturities most closely corresponding to the Comparable Treasury Issue shall be determined and the Treasury Rate shall be interpolated or extrapolated from those yields on a straight-line basis, rounding to the nearest month; or (2)&nbsp;if such
release (or any successor release) is not published during the week preceding the calculation date or does not contain such yields, the rate per year equal to the semiannual equivalent yield to maturity or interpolated (on a day count basis) of the
Comparable Treasury Issue, assuming a price for the applicable Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the applicable Comparable Treasury Price for such Redemption Date. The Treasury Rate shall be
calculated on the third business day preceding the Redemption Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Voting Stock&#148; means, with respect to any specified
&#147;person&#148; (as that term is used in Section&nbsp;13(d) of the Exchange Act) as of any date, the capital stock of such person that is at the time entitled to vote generally in the election of the board of directors of such person. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex4_1toc857739_4"></A>ARTICLE II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM AND TERMS OF THE NOTES </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="ex4_1toc857739_5">
</A>Section&nbsp;2.1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Form and Dating</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Notes due 2030 and the Trustee&#146;s certificate of
authentication shall be substantially in the form of <U>Exhibit A</U> attached hereto. The Notes due 2050 and the Trustee&#146;s certificate of authentication shall be substantially in the form of <U>Exhibit B</U> attached hereto. The Notes shall be
executed on behalf of the Company by an Officer of the Company. The Notes may have notations, legends or endorsements required by law, stock exchange rules or usage. Each Note shall be dated the date of its authentication. The Notes and any
beneficial interest in the Notes shall be in minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
terms and notations contained in the Notes shall constitute, and are hereby expressly made, a part of the Indenture as supplemented by this Second Supplemental Indenture and the Company and the Trustee, by their execution and delivery of this Second
Supplemental Indenture, expressly agree to such terms and provisions and to be bound thereby. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Global Notes</U>. The Notes of each Series designated herein
shall be issued initially in the form of one or more fully registered Global Securities, which shall be deposited on behalf of the purchasers of the Notes represented thereby with The Depository Trust Company, New York, New York (&#147;DTC&#148;)
and registered in the name of Cede&nbsp;&amp; Co., DTC&#146;s nominee, duly executed by the Company, authenticated by the Trustee and with guarantees endorsed thereon as hereinafter provided. The aggregate principal amount of outstanding Notes may
from time to time be increased or decreased by adjustments made on the records of the Trustee and DTC or its nominee as hereinafter provided. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Global Notes may not be transferred except by DTC, in whole and not in part, to another nominee of DTC or to a successor of DTC or its
nominee. If at any time DTC for the Notes notifies the Company that DTC is unwilling to continue as the depositary for the Global Notes or ceases to be a clearing agency, or if the Company so elects or if there is an Event of Default under the
Notes, then the Company shall execute, and the Trustee shall, upon receipt of a Company Order for authentication, authenticate and deliver, Definitive Notes in an aggregate principal amount equal to the principal amount of the Global Notes in
exchange for such Global Note, which DTC will distribute to its participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Book-Entry Provisions</U>.
This Section&nbsp;2.1(b) shall apply only to the Global Notes deposited with or on behalf of DTC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company shall execute and the
Trustee shall, in accordance with this Section&nbsp;2.1(b), authenticate and deliver the Global Notes that shall be registered in the name of DTC or the nominee of DTC and shall be delivered by the Trustee to DTC or pursuant to DTC&#146;s
instructions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depositary participants shall have no rights either under the Indenture or with respect to any Global Notes held on their
behalf by DTC or under such Global Notes. DTC shall be treated by the Company, the Trustee and any agent of the Company or the Trustee as the absolute owner of such Global Note for all purposes under the Indenture. Notwithstanding the foregoing,
nothing herein shall prevent the Company or the Trustee from giving effect to any written certification, proxy or other authorization furnished by DTC or impair, as between DTC and the depositary participants, the operation of customary practices of
such DTC governing the exercise of the rights of an owner of a beneficial interest in the Global Notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Definitive Notes</U>. Notes issued in certificated form shall be substantially in the form of Exhibit A or
Exhibit B, as applicable, attached hereto, but without including the text referred to therein as applying only to Global Notes. Except as provided above in subsection (a), owners of beneficial interests in the Global Notes will not be entitled to
receive physical delivery of certificated Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Transfer and Exchange of the Notes</U>. The transfer and
exchange of beneficial interests in the Global Notes shall be effected through DTC, in accordance with the Indenture and the procedures of DTC therefor. Beneficial interests in the Global Notes may be transferred to Persons who take delivery thereof
in the form of a beneficial interest in the Global Notes. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Paying Agent</U>. The Company appoints the Trustee as the
initial agent of the Company for the payment of the principal of (and premium, if any) and interest on the Notes and the Corporate Trust Office of the Trustee in St. Paul, Minnesota, be and hereby is, designated as the office or agency where the
Notes may be presented for payment and where notices to or demands upon the Company in respect of the Notes and the Indenture pursuant to which the Notes are to be issued may be served. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="ex4_1toc857739_6"></A>Section&nbsp;2.2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Terms of the Notes</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following terms relating to the Notes are hereby established: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<U>Title</U>. The Notes due 2030 shall constitute a Series of Securities having the title &#147;2.250% Senior Notes
due 2030&#148; and the Notes due 2050 shall constitute a separate Series of Securities having the title &#147;3.150% Senior Notes due 2050&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<U>Principal Amount</U>. The aggregate principal amount of the Notes due 2030 that may be initially authenticated
and delivered under the Indenture (except for Notes due 2030 authenticated and delivered upon registration of, transfer of, or in exchange for, or in lieu of, other Notes due 2030 pursuant to Sections 2.7, 2.8, 2.11, 3.6 or 8.5 of the Indenture)
shall be $1,500,000,000. The aggregate principal amount of the Notes due 2050 that may be initially authenticated and delivered under the Indenture (except for Notes due 2050 authenticated and delivered upon registration of, transfer of, or in
exchange for, or in lieu of, other Notes due 2050 pursuant to Sections 2.7, 2.8, 2.11, 3.6 or 8.5 of the Indenture) shall be $1,500,000,000. The Company may from time to time, without the consent of the Holders of Notes of any Series, issue
additional Notes (in any such case &#147;Additional Notes&#148;) of any Series having the same ranking and the same interest rate, maturity and other terms as the Notes of that Series. Any additional Notes of a Series and the existing Notes of that
Series will constitute a single Series under the Indenture and all references to the relevant Notes shall include the Additional Notes unless the context otherwise requires; <U>provided</U>, that if the Additional Notes of any Series are not
fungible with the Notes of such Series for U.S. federal income tax purposes, the Additional Notes will have a separate CUSIP number. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<U>Issuance Price</U>. The Notes due 2030 shall be issued at a price to the public of 99.973% of the principal
amount of such Series and the Notes due 2050 shall be issued at a price to the public of 99.174% of the principal amount of such Series, plus, in each case, accrued interest, if any, from April&nbsp;30, 2020 to the Original Issue Date (as defined in
the Note of the applicable Series). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<U>Maturity Date</U>. The entire outstanding principal of the Notes due
2030 shall be payable on May&nbsp;1, 2030 and the entire outstanding principal of the Notes due 2050 shall be payable on May&nbsp;1, 2050. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<U>Interest Rate; Place and Method of Payment</U>. The rate at which the Notes due 2030 shall bear interest shall
be 2.250% per annum and the rate at which the Notes due 2050 shall bear interest shall be 3.150% per annum; the date from which interest shall accrue on the Notes shall be April&nbsp;30, 2020, or the most recent Interest Payment Date to which
interest has been paid or provided for; the Interest Payment Dates for the Notes shall be November&nbsp;1 and May&nbsp;1 of each year, beginning November&nbsp;1, 2020; the interest so payable, and punctually paid or duly provided for, on any
Interest Payment Date, will be paid, in immediately available funds, to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Persons in whose names the Notes (or one or more predecessor Securities) is registered at the close of business on the Regular Record Date for such interest, which shall be October&nbsp;15 or
April&nbsp;15, as the case may be, next preceding such Interest Payment Date. Any such interest not punctually paid or duly provided for shall forthwith cease to be payable to the respective Holders on such Regular Record Date, and such defaulted
interest, may be paid to the Persons in whose names the Notes (or one or more predecessor Securities) is registered at the close of business on a special record date for the payment of such defaulted interest to be fixed by the Trustee, notice
whereof shall be given to Holders of Notes not less than 15 days prior to such special record date, or may be paid at any time in any other lawful manner not inconsistent with requirements of any securities exchange on which the Notes may be listed,
and upon such notice as may be required by such exchange, all as more fully provided in said Indenture. Payment of principal and interest on this Note will be made at the Corporate Trust Office of the Trustee or such other office or agency of the
Company as may be designated for such purpose, in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private debts; <U>provided</U>, <U>however</U>, that each installment of
interest and principal on the Notes may at the Company&#146;s option be paid in immediately available funds by transfer to an account maintained by the payee located in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<U>Optional Redemption</U>. The Notes of each Series are redeemable at the option of the Company on the terms and
conditions described in Section&nbsp;2.3 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<U>Sinking Fund Obligation</U>. There is no sinking fund
obligation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<U>Mandatory Redemption or Repurchase</U>. The Company shall be required to make an offer to
repurchase the Notes of any Series upon the occurrence of a Change of Control Triggering Event on the terms and conditions described in Section&nbsp;2.4 hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<U>Form and Denomination of Notes</U>. The Notes of each Series shall be issued in registered form in the
denominations specified in Section&nbsp;2.1 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<U>Principal Payable Upon Acceleration</U>. The entire
principal amount of, and premium, if any, on all the Notes of any Series then outstanding is payable upon acceleration of such Notes in accordance with Section&nbsp;6.2 of the Indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<U>Currency</U>. The currency of denomination of the Notes is United States Dollars. Payment of principal of and
interest and premium, if any, on the Notes will be made in United States Dollars. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment Not Made by
Reference to Index</U>. Payments of principal of or interest or premium, if any, on the Notes of any Series shall not be determined by reference to any index. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<U>Notes Unsecured</U>. Except as otherwise required pursuant to Section&nbsp;2.5 hereof, the Notes are not secured
by any collateral. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional/Different Covenants</U>. In addition to the covenants set forth in Indenture,
the Company shall be subject to the obligations set forth in Sections 2.3, 2.4, 2.5, 2.6 and 2.7 hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o)&nbsp;&nbsp;&nbsp;&nbsp;<U>Modification to Events of Default</U>. There is no addition
to, deletion of or change in (i)&nbsp;any Events of Default as applicable to the Notes of any Series as set forth under the Indenture or (ii)&nbsp;the right of the Trustee or the requisite Holders of any Series of Notes to declare the principal
amount thereof due and payable pursuant to Section&nbsp;6.2 of the Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p)&nbsp;&nbsp;&nbsp;&nbsp;<U>Conversion</U>. No Notes of
any Series are convertible or exchangeable for shares of common stock or preferred stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q)&nbsp;&nbsp;&nbsp;&nbsp;<U>Depositories and Agents</U>. The Notes of each Series shall be deposited with The Depository Trust Company,
acting as depositary, as described in Section&nbsp;2.1(a) hereof. The Company appoints the Trustee as initial paying agent for the Notes as described in Section&nbsp;2.1(e) hereof. There is no interest rate calculation agent, exchange rate
calculation agent or other agent with respect to the Notes of any Series other than those appointed herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r)&nbsp;&nbsp;&nbsp;&nbsp;<U>Subordination</U>. The Notes are not subordinated in right of payment to any other unsecured Indebtedness of the
Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s)&nbsp;&nbsp;&nbsp;&nbsp;<U>Defeasance</U>. The Notes of any Series are defeasible pursuant to Article 9 of the Indenture.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="ex4_1toc857739_7"></A>Section&nbsp;2.3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Optional Redemption</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The provisions of Article 3 of the Indenture shall apply to the Notes, except that, solely with respect to the
Notes, the third sentence of Section&nbsp;3.1 of the Indenture shall be substituted with the following: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;If a Series of Securities
is redeemable and the Company elects to redeem such Securities of a Series, it shall notify the Trustee of the Redemption Date and the principal amount of Securities to be redeemed at least 15 days (unless a shorter notice period shall be
satisfactory to the Trustee) before the Redemption Date.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;At any time prior to the Par Call Date
applicable to a Series of Notes, from time to time, the Notes are redeemable, as a whole or in part, at the Company&#146;s option, on at least 10 days, but not more than 60 days, prior notice mailed to the registered address of each Holder of the
Notes to be redeemed (or otherwise delivered in accordance with the applicable procedures of DTC), at a redemption price equal to the greater of: (i) 100% of principal amount of the Notes to be redeemed, or (ii)&nbsp;the sum of the present values of
the remaining scheduled payments (through the Par Call Date assuming for such purpose that such Notes matured on the applicable Par Call Date) of interest and principal thereon (exclusive of interest accrued and unpaid to, but not including, the
date of redemption) discounted to the date of redemption on a semiannual basis, assuming a <FONT STYLE="white-space:nowrap">360-day</FONT> year consisting of twelve <FONT STYLE="white-space:nowrap">30-day</FONT> months, at the Treasury Rate plus 25
basis points, in the case of Notes due 2030, and 30 basis points, in the case of Notes due 2050, plus, in either case, accrued and unpaid interest to, but not including, the date of redemption. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;In addition, at any time on or after the Par Call Date applicable to a Series of Notes, the Notes may be redeemed,
as a whole or in part, at the Company&#146;s option, on at least 10 days, but not more than 60 days, prior notice mailed to the registered address of each Holder of the Notes to be redeemed (or otherwise delivered in accordance with the applicable
procedures of DTC), at a redemption price equal to 100% of the principal amount of the Notes to be redeemed on the Redemption Date plus accrued and unpaid interest to, but not including, the date of redemption.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;On and after the Redemption Date for the Notes of any Series,
interest will cease to accrue on the Notes of such Series or any portion thereof called for redemption, unless the Company defaults in the payment of the redemption price. On or before the Redemption Date for the Notes of such Series, the Company
will deposit with a Paying Agent, or the Trustee, funds sufficient to pay the redemption price of the Notes to be redeemed on such date. If less than all of the Notes of a Series are to be redeemed, the Notes of that Series to be redeemed will be
selected by DTC in accordance with its standard procedures. If the Notes to be redeemed are not global notes then held by DTC, or DTC prescribes no method of selection, the Trustee will select the Notes to be redeemed on a pro rata basis, by lot, or
by any other method the Trustee deems fair and appropriate and subject to and otherwise in accordance with the procedures of DTC. Any redemption or notice of redemption may, at the Company&#146;s discretion, be subject to one or more conditions
precedent, and, at the Company&#146;s discretion, the Redemption Date may be delayed until such time as any or all such conditions shall be satisfied. The Company will provide written notice to the Trustee prior to the close of business two Business
Days prior to the Redemption Date if any such redemption has been rescinded or delayed, and upon receipt the Trustee shall provide such notice to each Holder of the Notes in the same manner in which the notice of redemption was given. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="ex4_1toc857739_8"></A>Section&nbsp;2.4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Repurchase of Notes Upon a Change of Control</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;If a Change of Control Triggering Event occurs with respect to the Notes of a Series, unless the Company has
exercised its option to redeem the Notes of such Series as described above, the Company will be required to make an offer (the &#147;Change of Control Offer&#148;) to each Holder of the Notes of such Series to repurchase all or any part (equal to
$2,000 or an integral multiple of $1,000 in excess thereof) of that Holder&#146;s Notes of such Series on the terms set forth in such Notes. In the Change of Control Offer, the Company will be required to offer payment in cash equal to 101% of the
aggregate principal amount of Notes repurchased, plus accrued and unpaid interest, if any, on the Notes repurchased to but not including the date of repurchase (the &#147;Change of Control Payment&#148;). With respect to the Notes of each Series,
within 30 days following any Change of Control Triggering Event or, at the Company&#146;s option, prior to any Change of Control, but after public announcement of the transaction that constitutes or may constitute the Change of Control, a notice
will be mailed (or otherwise delivered in accordance with the applicable procedures of DTC) to Holders of the Notes of the applicable Series describing the transaction that constitutes or may constitute the Change of Control Triggering Event and
offering to repurchase the Notes of such Series on the date specified in the notice, which date will be no earlier than 10 days and no later than 60 days from the date such notice is mailed (or otherwise delivered in accordance with the applicable
procedures of DTC) or, if the notice is mailed (or otherwise delivered) prior to the Change of Control, no earlier than 10 days and no later than 60 days from the date on which the Change of Control Triggering Event occurs (the &#147;Change of
Control Payment Date&#148;). The notice will, if mailed (or otherwise delivered) prior to the date of consummation of the Change of Control, state that the offer to purchase is conditioned on the Change of Control Triggering Event occurring on or
prior to the Change of Control Payment Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;On the Change of Control Payment Date, the Company shall, to the
extent lawful: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(1)&nbsp;&nbsp;&nbsp;&nbsp;accept for payment all Notes or portions of Notes properly tendered pursuant to the Change of
Control Offer; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(2)&nbsp;&nbsp;&nbsp;&nbsp;deposit with the Paying Agent an amount equal to the Change of Control Payment in respect of
all Notes or portions of Notes properly tendered; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(3)&nbsp;&nbsp;&nbsp;&nbsp;deliver or cause to be delivered to the Trustee the
Notes properly accepted together with an Officers&#146; Certificate stating the aggregate principal amount of Notes or portions of Notes being repurchased. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall not be required to make a Change of Control Offer upon the occurrence of a Change of Control
Triggering Event if a third party makes such an offer in the manner, at the times and otherwise in compliance with the requirements for an offer made by the Company and the third party repurchases all Notes properly tendered and not withdrawn under
its offer. In addition, the Company shall not repurchase any Notes if there has occurred and is continuing on the Change of Control Payment Date an Event of Default under the Indenture, other than an Event of Default arising as a result of a default
in the payment of the Change of Control Payment upon a Change of Control Triggering Event. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;The Company shall
comply in all material respects with the requirements of Rule <FONT STYLE="white-space:nowrap">14e-1</FONT> under the Exchange Act and any other securities laws and regulations thereunder to the extent such laws and regulations are applicable in
connection with the repurchase of the Notes as a result of a Change of Control Triggering Event. To the extent that the provisions of any such securities laws or regulations conflict with the Change of Control Offer provisions of the Notes, the
Company shall comply with the applicable securities laws and regulations and shall not be deemed to have breached its obligations under the Change of Control Offer provisions of the Notes by virtue of any such conflict. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="ex4_1toc857739_9"></A>Section&nbsp;2.5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation on Liens</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the benefit of the Holders of the Notes, a new Section&nbsp;4.7 shall be added to the Indenture as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Other than as provided in Section&nbsp;4.9, the Company shall not, and shall not permit any Subsidiaries of the Company to, create or
assume any Indebtedness secured by any Lien on any of the Company&#146;s or such Subsidiary&#146;s respective Principal Properties unless the Notes are secured by such Lien equally and ratably with, or prior to, the Indebtedness secured by such
Lien. This restriction does not apply to Indebtedness that is secured by (i)&nbsp;Liens existing on the date of the issuance of the Notes; (ii)&nbsp;Liens securing only the Notes; (iii)&nbsp;Liens on property or shares of stock in respect of
Indebtedness of a Person existing at the time such Person becomes a Subsidiary of the Company or is merged into or consolidated with, or its assets are acquired by, the Company or any Subsidiary of the Company (<U>provided</U> that such Lien was not
incurred in anticipation of such transaction and was in existence prior to such transaction) so long as such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Lien does not extend to any other property and the Indebtedness so secured is not increased; (iv)&nbsp;Liens to secure Indebtedness incurred for the purpose of all or any part of a
property&#146;s purchase price or cost of construction or additions, repairs, alterations, or other improvements; <U>provided</U> that (1)&nbsp;the principal amount of any Indebtedness secured by such Lien does not exceed 100% of such
property&#146;s purchase price or cost, (2)&nbsp;such Lien does not extend to or cover any other property other than the property so purchased, constructed or on which such additions, repairs, alterations or other improvements were so made, and
(3)&nbsp;such Lien is incurred prior to or within 270 days after the acquisition of such property or the completion of construction or such additions, repairs, alterations or other improvements and the full operation of such property thereafter;
(v)&nbsp;Liens in favor of the United States or any state thereof, or any instrumentality of either, to secure certain payments pursuant to any contract or statute; (vi)&nbsp;Liens for taxes or assessments or other governmental charges or levies
which are not overdue for a period exceeding 60 days unless such Liens are being contested in good faith and for which adequate reserves are being maintained, to the extent required by generally accepted accounting principles; (vii)&nbsp;title
exceptions, easements, licenses, leases and other similar Liens that are not consensual and that do not materially impair the use of the property subject thereto; (viii)&nbsp;Liens to secure obligations under worker&#146;s compensation laws,
unemployment compensation, <FONT STYLE="white-space:nowrap">old-age</FONT> pensions and other social security benefits or similar legislation; (ix)&nbsp;Liens arising out of legal proceedings, including Liens arising out of judgments or awards;
(x)&nbsp;warehousemen&#146;s, materialmen&#146;s, carrier&#146;s, landlord&#146;s and other similar Liens for sums not overdue for a period exceeding 60 days unless such Liens are being contested in good faith and for which adequate reserves are
being maintained, to the extent required by generally accepted accounting principles; (xi)&nbsp;Liens incurred to secure the performance of statutory obligations, surety or appeal bonds, performance or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">return-of-money</FONT></FONT> bonds, insurance, self-insurance or other obligations of a like nature incurred in the ordinary course of business; (xii)&nbsp;Liens that are rights of
<FONT STYLE="white-space:nowrap">set-off</FONT> relating to the establishment of depository relations with banks not given in connection with the issuance of Indebtedness; (xiii)&nbsp;Liens arising out of conditional sale, title retention,
consignment or similar arrangements for the sale of goods entered into by the Company or any of its Subsidiaries in the ordinary course of business; (xiv)&nbsp;Liens in favor of the Company or the favor of any of its Subsidiaries; or (xv)&nbsp;Liens
to secure any extension, renewal, refinancing or refunding (or successive extensions, renewals, refinancings or refundings), in whole or in part, of any Indebtedness secured by Liens referred to in clauses (i)&nbsp;to (xv) or Liens created in
connection with any amendment, consent or waiver relating to such Indebtedness, so long as such Lien does not extend to any other Principal Property and the Indebtedness so secured does not exceed the fair market value (as determined by the
Company&#146;s board of directors) of the assets subject to such Liens at the time of such extension, renewal, refinancing or refunding, or such amendment, consent or waiver, as the case may be.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="ex4_1toc857739_10"></A>Section&nbsp;2.6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Limitation on Sale and Leaseback Transactions</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the benefit of the Holders of the Notes a new Section&nbsp;4.8 shall be added to the Indenture as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Other than as provided under Section&nbsp;4.9, the Company shall not, and shall not permit any of its Subsidiaries to, enter into any
Sale and Leaseback Transaction with respect to any of the Company&#146;s or such Subsidiary&#146;s respective Principal Properties, the acquisition or completion of construction and commencement of full operations of which has occurred more
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
than 270 days prior thereto, unless (i)&nbsp;such transaction is entered into prior to the first issue date of the Notes; (ii)&nbsp;such transaction is for the sale and leasing back to the
Company of any property by one of its Subsidiaries; (iii)&nbsp;the Company or such Subsidiary is entitled to incur Indebtedness secured by a mortgage on the property to be leased in an amount equal to the Attributable Debt with respect to such Sale
and Leaseback Transaction without equally and ratably securing the Notes pursuant to the first sentence of Section&nbsp;4.7; (iv) the lease is for a period not in excess of five years, including renewal rights; or (v)&nbsp;the Company or the
Subsidiary, prior to or within 270 days after the sale of such property in connection with the Sale and Leaseback Transaction is completed, applies the net cash proceeds of the sale of the property leased to (1)&nbsp;the retirement of the Notes or
debt of the Company ranking equally with the Notes or to the retirement of any debt of a Subsidiary of the Company, or (2)&nbsp;the acquisition of another Principal Property.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="ex4_1toc857739_11"></A>Section&nbsp;2.7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Exempted Liens and Sale and Leaseback Transactions</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the benefit of the Holders of the Notes a new Section&nbsp;4.9 shall be added to the Indenture as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Notwithstanding the restrictions described under Sections 4.7 or 4.8, the Company or any Subsidiary of the Company may create or assume
any Liens or enter into any Sale and Leaseback Transactions not otherwise permitted as described above, if the sum of the following does not exceed 15% of Consolidated Total Assets (i)&nbsp;the outstanding Indebtedness secured by such Liens (not
including any Liens permitted under Section&nbsp;4.7 which amount does not include any Liens permitted under the provisions of this Section&nbsp;4.9); plus (ii)&nbsp;all Attributable Debt in respect of such Sale and Leaseback Transaction entered
into (not including any Sale and Leaseback Transactions permitted under Section&nbsp;4.8 which amount does not include any Sale and Leaseback Transactions permitted under the provisions of this Section&nbsp;4.9), measured, in each case, at the time
such Lien is incurred or any such Sale and Leaseback Transaction is entered into by the Company or such Subsidiary of the Company.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="ex4_1toc857739_12">
</A>Section&nbsp;2.8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Other Amendments</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the benefit of the Holders of the Notes Section&nbsp;2.3 of the
Indenture shall be amended by amending and restating the first paragraph of such Section in its entirety as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;The Securities
shall be executed on behalf of the Company by an Officer of the Company. Such signature may be either manual or facsimile.&#148; </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="ex4_1toc857739_13">
</A>ARTICLE III </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MISCELLANEOUS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="ex4_1toc857739_14">
</A>Section&nbsp;3.1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Trust Indenture Act Controls</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any provision of this Second Supplemental Indenture
limits, qualifies or conflicts with another provision which is required to be included in this Second Supplemental Indenture by the TIA, the required provision shall control. If any provision of this Second Supplemental Indenture modifies or
excludes any provision of the TIA which may be so modified or excluded, the latter provision shall be deemed to apply to this Second Supplemental Indenture as so modified or to be excluded, as the case may be.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="ex4_1toc857739_15"></A>Section&nbsp;3.2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Governing Law</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Second Supplemental Indenture and the Notes shall be governed by and construed in accordance with the laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="ex4_1toc857739_16"></A>Section&nbsp;3.3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Multiple Counterparts</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The parties may sign multiple counterparts of this Second Supplemental Indenture. Each signed counterpart shall be deemed an original, but all
of them together represent one and the same Second Supplemental Indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="ex4_1toc857739_17"></A>Section&nbsp;3.4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Severability</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each provision of this Second Supplemental Indenture shall be considered separable and if for any reason any provision which is not essential
to the effectuation of the basic purpose of this Second Supplemental Indenture or the Notes shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or
impaired thereby and a Holder shall have no claim therefor against any party hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="ex4_1toc857739_18"></A>Section&nbsp;3.5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Ratification</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Indenture, as supplemented and amended by this Second Supplemental Indenture, is in all respects ratified and confirmed. The Indenture and
this Second Supplemental Indenture shall be read, taken and construed as one and the same instrument. All provisions included in this Second Supplemental Indenture supersede any conflicting provisions included in the Indenture unless not permitted
by law. The Trustee accepts the trusts created by the Indenture, as supplemented by this Second Supplemental Indenture, and agrees to perform the same upon the terms and conditions of the Indenture, as supplemented by this Second Supplemental
Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="ex4_1toc857739_19"></A>Section&nbsp;3.6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Effectiveness</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions of this Second Supplemental Indenture shall become effective as of the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><A NAME="ex4_1toc857739_20"></A>Section&nbsp;3.7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Notices, Approvals, etc.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notices, approvals, consents, requests and any communications hereunder must be in writing (<U>provided</U> that any communication sent to the
Trustee hereunder must be in the form of a document that is signed manually or by way of a digital signature provided by Adobe or DocuSign (or such other digital signature provider as specified in writing to the Trustee by the authorized
representative), in English.&nbsp;The Company agrees to assume all risks arising out of the use of digital signatures and electronic methods to submit communications to the Trustee, including without limitation the risk of the Trustee acting on
unauthorized instructions, and the risk of interception and misuse by third parties. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of page intentionally left blank.] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Second Supplemental Indenture to be
duly executed as of the date first above written. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:53%; font-size:10pt; font-family:Times New Roman">BIOGEN INC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:53%; font-size:10pt; font-family:Times New Roman">By: <U>/s/ Michael
Dambach</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U><U>&nbsp;&nbsp;&nbsp;&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:53%; font-size:10pt; font-family:Times New Roman">Name: Michael Dambach </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:53%; font-size:10pt; font-family:Times New Roman">Title:&nbsp;&nbsp;&nbsp;&nbsp;Vice President, Treasurer </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; margin-left:53%; font-size:10pt; font-family:Times New Roman">U.S. BANK NATIONAL ASSOCIATION, as Trustee </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:53%; font-size:10pt; font-family:Times New Roman">By: <U>/s/</U><U></U><U>&nbsp;Laura S. Cawley</U><U>&nbsp;</U>&nbsp;&nbsp;&nbsp;&nbsp;<U> </U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:53%; font-size:10pt; font-family:Times New Roman">Name: Laura S. Cawley </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:53%; font-size:10pt; font-family:Times New Roman">Title:&nbsp;&nbsp;&nbsp;&nbsp;Vice President </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="ex4_1toc857739_21"></A>EXHIBIT A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF 2.250% SENIOR NOTE DUE 2030 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS NOTE IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF DTC OR A NOMINEE
OF DTC. THIS NOTE IS EXCHANGEABLE FOR NOTES REGISTERED IN THE NAME OF A PERSON OTHER THAN DTC OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY DTC TO A NOMINEE OF DTC, BY A
NOMINEE OF DTC TO DTC OR ANOTHER NOMINEE OF DTC OR BY DTC OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH A SUCCESSOR DEPOSITARY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">UNLESS THIS GLOBAL SECURITY IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION
(&#147;DTC&#148;), TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY GLOBAL SECURITY ISSUED IS REGISTERED IN THE NAME OF CEDE&nbsp;&amp; CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF
DTC (AND ANY PAYMENT IS MADE TO CEDE&nbsp;&amp; CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE
REGISTERED OWNER HEREOF, CEDE&nbsp;&amp; CO., HAS AN INTEREST HEREIN. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIOGEN INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2.250% Senior Note due 2030 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">REGISTERED</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">PRINCIPAL AMOUNT</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">No. Specimen</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman" ALIGN="right">$ [ ]</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CUSIP: [ ]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">ISIN: [ ]</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biogen Inc., a Delaware corporation (herein called the &#147;Company,&#148; which term includes any successor
Person under the Indenture hereinafter referred to), for value received, hereby promises to pay to Cede&nbsp;&amp; Co., or registered assigns, the principal sum of $[&nbsp;] on May&nbsp;1, 2030 (the &#147;Maturity Date&#148;) (except to the extent
redeemed or repaid prior to the Maturity Date) and to pay interest thereon from April&nbsp;30, 2020 (the &#147;Original Issue Date&#148;) or from the most recent Interest Payment Date to which interest has been paid or duly provided for
semi-annually at the rate of 2.250% per annum, on November&nbsp;1 and May&nbsp;1 (each such date, an &#147;Interest Payment Date&#148;), commencing November&nbsp;1, 2020, until the principal hereof is paid or made available for payment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Payment of Interest</U>. The interest so payable, and punctually paid or made available
for payment, on any Interest Payment Date, will, as provided in the Indenture, be paid, in immediately available funds, to the Person in whose name this Note (or one or more Predecessor Securities) is registered at the close of business on
October&nbsp;15 or April&nbsp;15 (whether or not a Business Day, as defined in the Indenture), as the case may be, next preceding such Interest Payment Date (the &#147;Regular Record Date&#148;). Any such interest not punctually paid or duly
provided for (&#147;Defaulted Interest&#148;) will forthwith cease to be payable to the Holder on such Regular Record Date, and such Defaulted Interest, may be paid to the Person in whose name this Note (or one or more Predecessor Securities) is
registered at the close of business on a special record date (the &#147;Special Record Date&#148;) for the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Notes not less than fifteen days
prior to such Special Record Date, or may be paid at any time in any other lawful manner not inconsistent with requirements of any securities exchange on which the Notes may be listed, and upon such notice as may be required by such exchange, all as
more fully provided in said Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Place of Payment</U>. Payment of principal, premium, if any, and interest on this Note will be
made at the Corporate Trust Office of the Trustee or such other office or agency of the Company as may be designated for such purpose, in such coin or currency of the United States of America as at the time of payment is legal tender for payment of
public and private debts; <U>provided</U>, <U>however</U>, that each installment of interest, premium, if any, and principal on this Note may at the Company&#146;s option be paid in immediately available funds by transfer to an account maintained by
the payee located in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Time of Payment</U>. In any case where any Interest Payment Date, the Maturity Date or any
date fixed for redemption or repayment of the Notes shall not be a Business Day, then (notwithstanding any other provision of the Indenture or this Note), payment of principal or interest, if any, need not be made on such date, but may be made on
the next succeeding Business Day with the same force and effect as if made on such Interest Payment Date, the Maturity Date or the date so fixed for redemption or repayment, and no interest shall accrue in respect of the delay. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>General</U>. This Note is one of a duly authorized issue of Securities of the Company, issued and to be issued in one or more Series under
an indenture, dated as of September&nbsp;15, 2015 (the &#147;Base Indenture&#148;), between the Company and U.S. Bank National Association (herein called the &#147;Trustee,&#148; which term includes any successor trustee under the Indenture with
respect to a Series of which this Note is a part), as supplemented by a Second Supplemental Indenture thereto, dated as of April&nbsp;30, 2020 (the &#147;Second Supplemental Indenture&#148; and, together with the Base Indenture, the
&#147;Indenture&#148;). Reference is hereby made to the Indenture for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee and the Holders of the Securities, and of the terms upon
which the Securities are, and are to be, authenticated and delivered. This Note is one of a duly authorized Series of Securities designated as &#147;2.250% Senior Notes due 2030&#148; (collectively, the &#147;Notes&#148;), initially limited in
aggregate principal amount to $1,500,000,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Further Issuance</U>. The Company may from time to time, without the consent of the
Holders of the Notes, issue additional Securities (the &#147;Additional Securities&#148;) of this Series having the same ranking and the same interest rate, maturity and other terms as the Notes. Any Additional Securities of this Series and the
Notes will constitute a single Series under the Indenture and all references to the Notes shall include the Additional Securities unless the context otherwise requires. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Events of Default</U>. If an Event of Default with respect to the Notes shall have
occurred and be continuing, the principal of the Notes may be declared due and payable in the manner and with the effect provided in the Indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Sinking Fund</U>. The Notes are not subject to any sinking fund. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Optional Redemption</U>. The Notes will be redeemable at any time, at the option of the Company, in whole or from time to time in part,
upon not less than 10 nor more than 60 days&#146; prior notice, on any date prior to their Maturity at a redemption price, calculated pursuant to the Indenture, which includes accrued interest thereon, if any, to, but not including, the Redemption
Date. In the case of any partial redemption, selection of the Notes for redemption will be made by the Trustee by such methods, as the Trustee in its sole discretion shall deem fair and appropriate. If any Note is to be redeemed in part only, the
notice of redemption relating to such Note shall state the portion of the principal amount thereof to be redeemed. A new Note in principal amount equal to the unredeemed portion thereof will be issued in the name of the Holder thereof upon
cancellation of this Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Repurchase upon a Change of Control Triggering Event</U>. Upon the occurrence of a Change of Control
Triggering Event with respect to the Notes, the Company shall be required to make an offer to repurchase the Notes on the terms set forth in the Indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Defeasance and Covenant Defeasance</U>. The Indenture contains provisions for defeasance at any time of (a)&nbsp;the entire indebtedness of
the Company on this Note and (b)&nbsp;certain restrictive covenants and the related Defaults and Events of Default, upon compliance by the Company with certain conditions set forth therein, which provisions apply to this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Modification and Waivers; Obligations of the Company Absolute</U>. The Indenture permits, with certain exceptions as therein provided, the
amendment thereof and the modification of the rights and obligations of the Company and the rights of the Holders of the Securities of each Series. Such amendment may be effected under the Indenture at any time by the Company, and the Trustee with
the consent of the Holders of not less than a majority in aggregate principal amount of the outstanding Notes of each Series affected thereby. The Indenture also contains provisions permitting the Holders of not less than a majority in aggregate
principal amount of the Securities at the time outstanding, on behalf of the Holders of all outstanding Securities, to waive compliance by the Company with certain provisions of the Indenture. Furthermore, provisions in the Indenture permit the
Holders of not less than a majority in aggregate principal amount of the outstanding Securities of individual Series to waive on behalf of all of the Holders of Securities of such individual Series certain past defaults under the Indenture and their
consequences. Any such consent or waiver shall be conclusive and binding upon the Holder of this Note and upon all future Holders of this Note and of any Note issued upon the registration of transfer hereof or in exchange hereof or in lieu hereof,
whether or not notation of such consent or waiver is made upon this Note. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No reference herein to the Indenture and no provision of this Note or of the Indenture shall
alter or impair the obligation of the Company, which is absolute and unconditional, to pay the principal of and interest on this Note at the time, place, and rate, and in the coin or currency, herein prescribed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Limitation on Suits</U>. As set forth in, and subject to, the provisions of the Indenture, no Holder of any Note will have any right to
institute any proceeding with respect to the Indenture or for any remedy thereunder, unless such Holder shall have previously given to the Trustee written notice of a continuing Event of Default with respect to this Series, the Holders of not less
than 25% in aggregate principal amount of the outstanding Notes shall have made written request, and offered indemnity and/or security, to the Trustee to institute such proceedings as trustee, and the Trustee shall not have received from the Holders
of a majority in principal amount of the outstanding Notes a direction inconsistent with such request and shall have failed to institute such proceeding within 60 days; <U>provided</U>, <U>however</U>, that such limitations do not apply to a suit
instituted by the Holder hereof for the enforcement of payment of the principal of or interest on this Note on or after the respective due dates expressed herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Authorized Denominations</U>. The Notes are issuable only in registered form without coupons in denominations of $2,000 or any integral
multiple of $1,000 in excess thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Registration of Transfer or Exchange</U>. As provided in the Indenture and subject to certain
limitations herein and therein set forth, the transfer of this Note is registrable in the register of the Notes maintained by the Registrar upon surrender of this Note for registration of transfer, at the office or agency of the Company in any place
where the principal of and interest on this Note are payable, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Registrar, duly executed by the Holder hereof or his attorney duly
authorized in writing, and thereupon one or more new Notes, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As provided in the Indenture and subject to certain limitations herein and therein set forth, the Notes are exchangeable for a like aggregate
principal amount of Notes of different authorized denominations, as requested by the Holders surrendering the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No service charge
shall be made for any such registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to due presentment of this Note for registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may
treat the Holder as the owner hereof for all purposes, whether or not this Note be overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice to the contrary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Defined Terms</U>. All terms used in this Note, which are defined in the Indenture and are not otherwise defined herein, shall have the
meanings assigned to them in the Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><U>Governing Law</U>. This Note shall be governed by and construed in accordance with the
laws of the State of New York.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the certificate of authentication hereon has been executed by the Trustee by manual
signature, this Note shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of
page intentionally left blank.] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed and its seal
to be hereunto affixed. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="50%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: April [ ], 2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; font-size:10pt; font-family:Times New Roman">BIOGEN INC.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:10pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:6.00em; font-size:10pt; font-family:Times New Roman">By:
&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center">TRUSTEE&#146;S CERTIFICATE OF AUTHENTICATION </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This is one of the Notes of the Series designated and referred to in the within-mentioned Indenture, as such is supplemented by the
within-mentioned Second Supplemental Indenture. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="50%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:6.00em; font-size:10pt; font-family:Times New Roman">U.S. BANK NATIONAL ASSOCIATION, as Trustee</P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:6.00em; font-size:10pt; font-family:Times New Roman">By: __________________________</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Name:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: April [ ], 2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:6.00em; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ASSIGNMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FOR VALUE RECEIVED, the undersigned hereby sell(s), assign(s) and transfer(s) unto </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLEASE INSERT SOCIAL SECURITY NUMBER OR OTHER IDENTIFYING NUMBER OF ASSIGNEE </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt; padding-right:2pt">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Please print or typewrite name and address, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">including postal zip code, of assignee) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the
within Note and all rights thereunder, and hereby irrevocably constitutes and appoints </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="99%"></TD></TR>


<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">to transfer said Note on the books of the Trustee, with full power of substitution in the premises. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: ______________________________________________</P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">_<BR></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:Times New Roman">_______________________________ <BR>NOTICE: The signature to this assignment must correspond with the name as
written upon the face of the within Note in every particular, without alteration or enlargement or any change whatsoever.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="68"></TD>
<TD HEIGHT="68" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">_____________________________________________________ <BR>Signature Guarantee</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><A NAME="ex4_1toc857739_22"></A>EXHIBIT B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF 3.150% SENIOR NOTE DUE 2050 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">THIS NOTE IS A GLOBAL SECURITY WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF DTC OR A NOMINEE
OF DTC. THIS NOTE IS EXCHANGEABLE FOR NOTES REGISTERED IN THE NAME OF A PERSON OTHER THAN DTC OR ITS NOMINEE ONLY IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY DTC TO A NOMINEE OF DTC, BY A
NOMINEE OF DTC TO DTC OR ANOTHER NOMINEE OF DTC OR BY DTC OR ANY SUCH NOMINEE TO A SUCCESSOR DEPOSITARY OR A NOMINEE OF SUCH A SUCCESSOR DEPOSITARY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">UNLESS THIS GLOBAL SECURITY IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION
(&#147;DTC&#148;), TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE OR PAYMENT, AND ANY GLOBAL SECURITY ISSUED IS REGISTERED IN THE NAME OF CEDE&nbsp;&amp; CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF
DTC (AND ANY PAYMENT IS MADE TO CEDE&nbsp;&amp; CO. OR TO SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE
REGISTERED OWNER HEREOF, CEDE&nbsp;&amp; CO., HAS AN INTEREST HEREIN. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BIOGEN INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3.150% Senior Note due 2050 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>REGISTERED</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>PRINCIPAL AMOUNT</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>No. Specimen</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>$[&nbsp;&nbsp;&nbsp;&nbsp;]</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>CUSIP: [&nbsp;&nbsp;&nbsp;&nbsp;] </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ISIN: [&nbsp;&nbsp;&nbsp;&nbsp;] </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Biogen
Inc., a Delaware corporation (herein called the &#147;Company,&#148; which term includes any successor Person under the Indenture hereinafter referred to), for value received, hereby promises to pay to Cede&nbsp;&amp; Co., or registered assigns, the
principal sum of $[&nbsp;] on May&nbsp;1, 2050 (the &#147;Maturity Date&#148;) (except to the extent redeemed or repaid prior to the Maturity Date) and to pay interest thereon from April&nbsp;30, 2020 (the &#147;Original Issue Date&#148;) or from
the most recent Interest Payment Date to which interest has been paid or duly provided for semi-annually at the rate of 3.150% per annum, on May&nbsp;1 and November&nbsp;1 (each such date, an &#147;Interest Payment Date&#148;), commencing
November&nbsp;1, 2020, until the principal hereof is paid or made available for payment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Payment of Interest</U>. The interest so payable, and punctually paid or made available
for payment, on any Interest Payment Date, will, as provided in the Indenture, be paid, in immediately available funds, to the Person in whose name this Note (or one or more Predecessor Securities) is registered at the close of business on
October&nbsp;15 or April&nbsp;15 (whether or not a Business Day, as defined in the Indenture), as the case may be, next preceding such Interest Payment Date (the &#147;Regular Record Date&#148;). Any such interest not punctually paid or duly
provided for (&#147;Defaulted Interest&#148;) will forthwith cease to be payable to the Holder on such Regular Record Date, and such Defaulted Interest, may be paid to the Person in whose name this Note (or one or more Predecessor Securities) is
registered at the close of business on a special record date (the &#147;Special Record Date&#148;) for the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to Holders of Notes not less than fifteen days
prior to such Special Record Date, or may be paid at any time in any other lawful manner not inconsistent with requirements of any securities exchange on which the Notes may be listed, and upon such notice as may be required by such exchange, all as
more fully provided in said Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Place of Payment</U>. Payment of principal, premium, if any, and interest on this Note will be
made at the Corporate Trust Office of the Trustee or such other office or agency of the Company as may be designated for such purpose, in such coin or currency of the United States of America as at the time of payment is legal tender for payment of
public and private debts; <U>provided</U>, <U>however</U>, that each installment of interest, premium, if any, and principal on this Note may at the Company&#146;s option be paid in immediately available funds by transfer to an account maintained by
the payee located in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Time of Payment</U>. In any case where any Interest Payment Date, the Maturity Date or any
date fixed for redemption or repayment of the Notes shall not be a Business Day, then (notwithstanding any other provision of the Indenture or this Note), payment of principal or interest, if any, need not be made on such date, but may be made on
the next succeeding Business Day with the same force and effect as if made on such Interest Payment Date, the Maturity Date or the date so fixed for redemption or repayment, and no interest shall accrue in respect of the delay. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>General</U>. This Note is one of a duly authorized issue of Securities of the Company, issued and to be issued in one or more Series under
an indenture, dated as of September&nbsp;15, 2015 (the &#147;Base Indenture&#148;), between the Company and U.S. Bank National Association (herein called the &#147;Trustee,&#148; which term includes any successor trustee under the Indenture with
respect to a Series of which this Note is a part), as supplemented by a Second Supplemental Indenture thereto, dated as of April&nbsp;30, 2020 (the &#147;Second Supplemental Indenture&#148; and, together with the Base Indenture, the
&#147;Indenture&#148;). Reference is hereby made to the Indenture for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company, the Trustee and the Holders of the Securities, and of the terms upon
which the Securities are, and are to be, authenticated and delivered. This Note is one of a duly authorized Series of Securities designated as &#147;3.150% Senior Notes due 2050&#148; (collectively, the &#147;Notes&#148;), initially limited in
aggregate principal amount to $1,500,000,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Further Issuance</U>. The Company may from time to time, without the consent of the
Holders of the Notes, issue additional Securities (the &#147;Additional Securities&#148;) of this Series having the same ranking and the same interest rate, maturity and other terms as the Notes. Any Additional Securities of this Series and the
Notes will constitute a single Series under the Indenture and all references to the Notes shall include the Additional Securities unless the context otherwise requires. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Events of Default</U>. If an Event of Default with respect to the Notes shall have
occurred and be continuing, the principal of the Notes may be declared due and payable in the manner and with the effect provided in the Indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Sinking Fund</U>. The Notes are not subject to any sinking fund. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Optional Redemption</U>. The Notes will be redeemable at any time, at the option of the Company, in whole or from time to time in part,
upon not less than 10 nor more than 60 days&#146; prior notice, on any date prior to their Maturity at a redemption price, calculated pursuant to the Indenture, which includes accrued interest thereon, if any, to, but not including, the Redemption
Date. In the case of any partial redemption, selection of the Notes for redemption will be made by the Trustee by such methods, as the Trustee in its sole discretion shall deem fair and appropriate. If any Note is to be redeemed in part only, the
notice of redemption relating to such Note shall state the portion of the principal amount thereof to be redeemed. A new Note in principal amount equal to the unredeemed portion thereof will be issued in the name of the Holder thereof upon
cancellation of this Note. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Repurchase upon a Change of Control Triggering Event</U>. Upon the occurrence of a Change of Control
Triggering Event with respect to the Notes, the Company shall be required to make an offer to repurchase the Notes on the terms set forth in the Indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Defeasance and Covenant Defeasance</U>. The Indenture contains provisions for defeasance at any time of (a)&nbsp;the entire indebtedness of
the Company on this Note and (b)&nbsp;certain restrictive covenants and the related Defaults and Events of Default, upon compliance by the Company with certain conditions set forth therein, which provisions apply to this Note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Modification and Waivers; Obligations of the Company Absolute</U>. The Indenture permits, with certain exceptions as therein provided, the
amendment thereof and the modification of the rights and obligations of the Company and the rights of the Holders of the Securities of each Series. Such amendment may be effected under the Indenture at any time by the Company, and the Trustee with
the consent of the Holders of not less than a majority in aggregate principal amount of the outstanding Notes of each Series affected thereby. The Indenture also contains provisions permitting the Holders of not less than a majority in aggregate
principal amount of the Securities at the time outstanding, on behalf of the Holders of all outstanding Securities, to waive compliance by the Company with certain provisions of the Indenture. Furthermore, provisions in the Indenture permit the
Holders of not less than a majority in aggregate principal amount of the outstanding Securities of individual Series to waive on behalf of all of the Holders of Securities of such individual Series certain past defaults under the Indenture and their
consequences. Any such consent or waiver shall be conclusive and binding upon the Holder of this Note and upon all future Holders of this Note and of any Note issued upon the registration of transfer hereof or in exchange hereof or in lieu hereof,
whether or not notation of such consent or waiver is made upon this Note. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No reference herein to the Indenture and no provision of this Note or of the Indenture shall
alter or impair the obligation of the Company, which is absolute and unconditional, to pay the principal of and interest on this Note at the time, place, and rate, and in the coin or currency, herein prescribed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Limitation on Suits</U>. As set forth in, and subject to, the provisions of the Indenture, no Holder of any Note will have any right to
institute any proceeding with respect to the Indenture or for any remedy thereunder, unless such Holder shall have previously given to the Trustee written notice of a continuing Event of Default with respect to this Series, the Holders of not less
than 25% in aggregate principal amount of the outstanding Notes shall have made written request, and offered indemnity and/or security, to the Trustee to institute such proceedings as trustee, and the Trustee shall not have received from the Holders
of a majority in principal amount of the outstanding Notes a direction inconsistent with such request and shall have failed to institute such proceeding within 60 days; <U>provided</U>, <U>however</U>, that such limitations do not apply to a suit
instituted by the Holder hereof for the enforcement of payment of the principal of or interest on this Note on or after the respective due dates expressed herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Authorized Denominations</U>. The Notes are issuable only in registered form without coupons in denominations of $2,000 or any integral
multiple of $1,000 in excess thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Registration of Transfer or Exchange</U>. As provided in the Indenture and subject to certain
limitations herein and therein set forth, the transfer of this Note is registrable in the register of the Notes maintained by the Registrar upon surrender of this Note for registration of transfer, at the office or agency of the Company in any place
where the principal of and interest on this Note are payable, duly endorsed by, or accompanied by a written instrument of transfer in form satisfactory to the Company and the Registrar, duly executed by the Holder hereof or his attorney duly
authorized in writing, and thereupon one or more new Notes, of authorized denominations and for the same aggregate principal amount, will be issued to the designated transferee or transferees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As provided in the Indenture and subject to certain limitations herein and therein set forth, the Notes are exchangeable for a like aggregate
principal amount of Notes of different authorized denominations, as requested by the Holders surrendering the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No service charge
shall be made for any such registration of transfer or exchange, but the Company may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection therewith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to due presentment of this Note for registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may
treat the Holder as the owner hereof for all purposes, whether or not this Note be overdue, and neither the Company, the Trustee nor any such agent shall be affected by notice to the contrary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Defined Terms</U>. All terms used in this Note, which are defined in the Indenture and are not otherwise defined herein, shall have the
meanings assigned to them in the Indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U><B>Governing Law. This Note shall be governed by and construed in accordance with the laws
of the State of New York.</B></U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the certificate of authentication hereon has been executed by the Trustee by manual
signature, this Note shall not be entitled to any benefit under the Indenture or be valid or obligatory for any purpose. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[Remainder of
page intentionally left blank.] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed and its seal
to be hereunto affixed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: April [&nbsp;&nbsp;&nbsp;&nbsp;], 2020 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">BIOGEN INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TRUSTEE&#146;S CERTIFICATE OF AUTHENTICATION </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This is one of the Notes of the Series designated and referred to in the within-mentioned Indenture, as such is supplemented by the
within-mentioned Second Supplemental Indenture. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">U.S. BANK NATIONAL ASSOCIATION, as Trustee</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title:</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: April [&nbsp;&nbsp;&nbsp;&nbsp;], 2020 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ASSIGNMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FOR VALUE RECEIVED, the undersigned hereby sell(s), assign(s) and transfer(s) unto </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLEASE INSERT SOCIAL SECURITY NUMBER OR OTHER
IDENTIFYING NUMBER OF ASSIGNEE </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="16%"></TD></TR>


<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1px; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Please print or typewrite name and address, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">including postal zip code, of assignee) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the
within Note and all rights thereunder, and hereby irrevocably constitutes and appoints </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">to transfer said Note on the books of the Trustee,
with full power of substitution in the premises. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">NOTICE: The signature to this assignment must correspond with the name as written upon the face of the within Note in every particular, without alteration or enlargement or any change whatsoever.</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Signature Guarantee</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">B-8 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>d857739dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">


<IMG SRC="g857739g61m31.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Seaport West <BR>155 Seaport Boulevard <BR>Boston, MA 02210-2600</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">617 832 1000 <I>main</I></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">617 832 7000 <I>fax</I></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">April&nbsp;30, 2020</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Biogen Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">225 Binney Street</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Cambridge, Massachusetts 02142</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">$1,500,000,000 2.250% Senior Notes due 2030 </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">$1,500,000,000 3.150% Senior Notes due 2050 </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen:<SUP STYLE="font-size:85%; vertical-align:top"> </SUP> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as counsel for Biogen Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), in connection with the offer and sale of
$1,500,000,000 aggregate principal amount of its 2.250% Senior Notes due 2030 and $1,500,000,000 aggregate principal amount of its 3.150% Senior Notes due 2050 (collectively, the &#147;<B>Notes</B>&#148;), pursuant to the Underwriting Agreement
dated as of April&nbsp;27, 2020 (the &#147;<B>Underwriting</B><B><I> </I></B><B>Agreement</B>&#148;) among the Company and Goldman, Sachs&nbsp;&amp; Co. LLC, BofA Securities, Inc. and J.P. Morgan Securities LLC, as representatives of the several
underwriters named in Schedule I to the Underwriting Agreement. The Notes are being issued pursuant to the Indenture dated as of September&nbsp;15, 2015 (the &#147;<B>Base Indenture</B>&#148;) between the Company and U.S. Bank National Association,
as trustee (the &#147;<B>Trustee</B>&#148;), as amended and supplemented by the Second Supplemental Indenture dated as of April&nbsp;30, 2020 (the &#147;<B>Supplemental Indenture</B>,&#148; and, together with the Base Indenture, the
&#147;<B>Indenture</B>&#148;) between the Company and the Trustee, as trustee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As such counsel, we have assisted in the preparation and
filing with the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) of (i)&nbsp;the Company&#146;s shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-237819)</FONT> (the &#147;<B>Registration Statement</B>&#148;) under the Securities Act of 1933, as amended (the &#147;<B>Securities Act</B>&#148;), filed by the Company on April&nbsp;24, 2020 and
(ii)&nbsp;the prospectus dated April&nbsp;24, 2020 (the &#147;<B>Base Prospectus</B>&#148;) that constitutes a part of the Registration Statement, as supplemented by the prospectus supplement dated April&nbsp;27, 2020 (the &#147;<B>Prospectus
Supplement</B>,&#148; and, collectively with the Base Prospectus, the &#147;<B>Prospectus</B>&#148;) filed by the Company pursuant to Rule 424(b) under the Securities Act on April&nbsp;28, 2020, in each case related to the offering of the Notes.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with this opinion, we have examined originals or copies, certified or otherwise identified to our satisfaction, of
(i)&nbsp;the amended and restated certificate of incorporation of the Company, as amended to the date hereof and on file with the Secretary of State of the State of Delaware, (ii)&nbsp;the amended and restated
<FONT STYLE="white-space:nowrap">by-laws</FONT> of the Company, as </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
amended to the date hereof, (iii)&nbsp;the Registration Statement, including the Base Prospectus and the documents and information incorporated by reference therein, (iv)&nbsp;the Prospectus,
(v)&nbsp;the Indenture, (vi)&nbsp;the Notes, (vii)&nbsp;the Form <FONT STYLE="white-space:nowrap">T-1</FONT> of the Trustee filed with the Commission with respect to the transaction, (viii)&nbsp;such records of the corporate proceedings of the
Company as we have deemed material, and (ix)&nbsp;such other certificates, receipts, records and documents as we have deemed necessary or appropriate for purposes of this opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In our examination, we have assumed the legal capacity of all natural persons, the genuineness of all signatures, the authenticity of all
documents submitted to us as originals and the conformity to authentic original documents of all documents submitted to us as copies. As to facts material to the opinions, statements and assumptions expressed herein, we have, with your consent,
relied upon oral or written statements and representations of officers and other representatives, and other information, of the Company and others. We have not independently verified such factual matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our opinion expressed below is qualified to the extent that (i)&nbsp;the enforceability or validity of any provision of any agreement,
instrument or document or any rights granted thereunder may be subject to or affected by any bankruptcy, insolvency, reorganization, moratorium, preference, fraudulent conveyance, fraudulent transfer or similar law relating to or affecting the
rights and remedies of creditors generally which may be in effect from time to time, (ii)&nbsp;the remedy of specific performance or any other equitable remedy may be unavailable in any jurisdiction or may be withheld as a matter of judicial
discretion, (iii)&nbsp;equitable principles and principles of public policy may be applied in construing or enforcing any of the provisions of any agreement, instrument or document, (iv)&nbsp;the enforceability, validity or binding effect of any
remedial provision of any agreement, instrument or document may be limited by applicable law, including, but not limited to, the application of principles of materiality, reasonableness, good faith and fair dealing, which may limit particular rights
and remedies but not so as to interfere materially with the practical realization of the benefits intended to be provided by such agreement, instrument or document, and (v)&nbsp;rights to indemnification and contribution may be limited by federal
and state securities laws or public policy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In rendering the opinions set forth below, we have assumed that (i)&nbsp;the Trustee is duly
organized, validly existing and in good standing under the laws of its jurisdiction of organization, (ii)&nbsp;the Trustee has the requisite organizational and legal power and authority to execute and deliver and to perform its obligations under the
Indenture, (iii)&nbsp;the Trustee is duly qualified to engage in the activities contemplated by the Indenture, (iv)&nbsp;the Indenture has been duly authorized, executed and delivered by the Trustee and constitutes the legally valid and binding
obligations of the Trustee, enforceable against the Trustee in accordance with its terms, and (v)&nbsp;the Trustee is in compliance, generally and with respect to acting as a trustee under the Indenture, with all applicable laws and regulations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are opining herein only as to the federal laws of the United States, the internal laws of the State of New York and the Delaware
General Corporation Law, and we express no opinion with respect to the laws of any other jurisdiction or, in the case of Delaware, any other laws, or as to any matters of municipal law or the laws of any other local agencies within any state. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the basis of, and subject to, the foregoing, we are of the opinion that when the Notes
have been duly executed by the Company, duly authenticated by the Trustee in accordance with the terms of the Indenture and delivered to the purchasers thereof against payment of the consideration therefor in accordance with the terms of the
Underwriting Agreement, the Notes will constitute binding obligations of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This opinion is based upon currently existing
statutes, rules and regulations and judicial decisions and is rendered as of the date hereof, and we disclaim any obligation to advise you of any change in any of the foregoing sources of law or subsequent developments in law or changes in facts or
circumstances which might affect any matters or opinions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We consent to your filing this opinion as an exhibit to the
Registration Statement and to the references to our firm in each of the Base Prospectus and the Prospectus Supplement under the heading &#147;Legal Matters.&#148; In giving such consent, we do not thereby admit that we are in the category of persons
whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations thereunder. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">FOLEY HOAG LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="54"></TD>
<TD HEIGHT="54" COLSPAN="2"></TD>
<TD HEIGHT="54" COLSPAN="2"></TD>
<TD HEIGHT="54" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ John D. Hancock</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">A partner</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>biib-20200427.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-3 Build:20200324.2 -->
<!-- Creation date: 4/30/2020 10:57:58 PM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2019-01-31"
  xmlns:biib="http://www.biogenidec.com/20200427"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.biogenidec.com/20200427"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2019-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20200427_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20200427_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>biib-20200427_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-3 Build:20200324.2 -->
<!-- Creation date: 4/30/2020 10:57:58 PM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>biib-20200427_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2020-3 Build:20200324.2 -->
<!-- Creation date: 4/30/2020 10:57:58 PM Eastern Time -->
<!-- Copyright (c) 2020 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="biib-20200427.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g857739g0430030203730.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g857739g0430030203730.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  D &8# 2(  A$! Q$!_\0
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)/2BBBE9 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g857739g61m31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g857739g61m31.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  P ),# 2(  A$! Q$!_\0
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MS_A7^S+XS^'WCW2_$&K?'+QAXQT^S\WS=%U1R;>YWQ.@W_O#]TL'''5!7._
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;7O$=M-)(T*%FDB6W*QL222H) )(S13L*Y__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d857739d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d857739d8k.htm">d857739d8k.htm</File>
    <File>biib-20200427.xsd</File>
    <File>biib-20200427_lab.xml</File>
    <File>biib-20200427_pre.xml</File>
    <File>d857739dex11.htm</File>
    <File>d857739dex42.htm</File>
    <File>d857739dex51.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g857739g0430030203730.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>11
<FILENAME>0001193125-20-128818-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-20-128818-xbrl.zip
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M@\PV)[FYZ4[\XFJQ<>CG#U!+ P04    " #&@IY0@$XT;F(&  !)1   %0
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M:]A_H:L6VJ*P5@\;M<I*)\&-;7*3524Y#&!"[._G02_7YIC)*0B60)R-JFP
M5)OUR\C0E10R74=6%=W*>)&",.ZW(Y([89A9]\1$JC3K2T"RM+9F"B;M8,S8
M.'31K*,/ PSTY9Q 9CW'0T.S=,XA(-%.C^8*1X\P6>T'+,@)8&5 ))"X,+8#
MWZS/-QNRV^$KXUP.W!&<8=/8W%2^1 DP;+%V93="NQ%6:UMH'[#H2U?BU-$9
M:Z-H;/*IX';42.4*.1T#;P<%HNB_M]7!%"0V#?><3D^UM2?*V]J%V%%Q+B15
ML0N'FP<$\\?!MD8TIPKCA?$,ISRGGBB9%J9HVYHL-"I5 JH=U.L5//X#,E=,
M*@2/)0%9:/0BY]8UY78?3$ I2!XVW3[J,K.(<ZF&K.8W@;09GUWLAZ*\AP?!
MZE=8GPKKB+B\T(X8=O :GL%S\\P(DWDJL[RFO*CR/AVA"T\)]0$=X\D@N<4K
MIW-1[8G+SVS/L(/WDV?P-K/% *;,=E>8)YJ>S*Y86UYTQ7X=N4LOR>$-A%1S
MJ;($#S'/T)4+G/K779F<"?(KH<K.]2OV'>:/7F*^9QR>%ND8U'E,=W5E![CK
MU=&Z\I+6B*YZ"2:#3=CFAO8MZ(X&*3O'H\:W4!M5+Z%VD@13K;<_>'\-M?.
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M/Z?BS/=<CH0H+\=7;3N<_\,RRG5TD)H'++#O<&[VV"_[1B*6_ U02P,$%
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M5]H5XEB-^MF.23DM(.4Q3PH26[KX<'/W>;DU?\_=&(UYSJFL;S&UPYHUE:_
M[H(U@A+<75W?D[NKVYN[^V\B\MLO=]TOET##_0T!K;P'U>L2NT9N[HC=./ .
MR<T'<O_+%<EI;*:ME^U[O&V?U>HK:7\FNXZ15K14A/?)'8NX4.0@O684+!63
MBK '&)H(?9MYATUR+B,:SA"5L.\=LL]0@#=!%0"9 ;A9J7"WVCY>&;.YJ>81
M P#?E@ T-CT88 3=AQZ=3& )+"Q=7$;"#XAS<D2PUZ*2XG)VK:O6*N9KWA.
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ML(Z#"]7S(U\Y\O!RR$QN#1G_PIU+4X7MJ^A-2<2U+(%'=]VS1W?==]4 NU5
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M<>N$*J,+3@W1?'93]/6M_76PY:\$*X'>B,(Y;OGJLHJY0@<,[2"WHNXH>CE
MO!3HN>)@9UO5IO8DU02CR59?#B_8G7X32*BBM.0-T[8P,FU+J_((6#>AE"=;
M)HO&>)-N6U%J3'%G:+L-%3-&N' EI.+08QVP]7@T $.$ZA 8C C,LD37IJS=
MZLHMK%Y;L>XR:[BTUL(BHR3F79(\X_0#$,E3+_W(ZW9=PS843DUMI(E5PT+C
MTO<]'U78R%BM>6_R\L;9!$$'.3FG(F.,6V8,(Z.\AFJL@DS !KM:EFF]*=E
MO:4U259!Q&I-B7"I3(Z%UH[:A8\#46MCC,'M\L4:S^-\"-T @ ;4RNZJT+)?
M9 &TU:O\#:38^6\T+@CJ5<9H%1JS6S0\6@7?)= T-?8'B'Y^="5*YT)!V&#W
M7..'2XA[P]$4)%4S27(>\^_64ZH@=W26L_.0POAR!M<V?E:O6*QJ!BAYC4*6
MA3@)7I>=Z_6U%H>IF@3-3*K@/5PAF@=%"Y=@G61T)1-,/D%GIT18Z_![UYG
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MGA>J*Q92\DE[$SUC8@^IGE74?LG/JU >H,9U4!UXF =BI)I%].^@[D6P"&=
MU/3'G_%@(G^>C6!:@TA\^'F"?]K4(X)G#O KFY#4BR9?V1' L1M2(H&5^3P6
M>9QJ@>&*(_"P<RD&'ZXTNJ2T? 7D2/EP*%"QJ'3S.H[J&_&X9ZUZII;.8N"3
MMM9FL;^^!_RZG5UG!AN_HMJSCTA2%>'8H,"S9>PJMW$@!<P7IB%,1HBD(CUU
MTP1U;K@;U,[3M5ZE414]'5.!I$.EB-<*O"B1!"ZU0YWA2XL831KW-9+L,$/X
M3@4F%-N395NIOV$\X*^4VRG)&:KEF\WIFTI1EU.D&CL>L(:\'Q5)OU),4%GC
M!3W9Z:193:9ET<6&Q-0.2B_AMF0*/D80]"1R3E,EEUR,]X75&Q.+O5=4[@P-
M<9,><SDR24*N^Q[7%+4U0+-9=-P,C^)FV 588\/+2GM+7U]VM8*5AQH*G.43
M!.7!A:&SV<^F25QX:V#(/A+^3QD*Q0CD0FCJC8BI9RG"OD929C+5R0.>A>[.
MB]V:!^L5VGWT"MUFRHP<T2I[5"37P!UW=[$;I,\=JY#,NOR.GH@1\3?V)>YH
M P<Q$0&;..K!3O/QJ9B])O.#X#E-;[>E1MHR!H-=;;1NYT[!Z[Y)2$BA6CDP
M]ZN,-V@9;J7GYEH$*O VMK&$_SS%=^L.G*LK'GPVQHG0''!<2'=MJ'C)R.F6
M!6E&V.L2G!2NCA%:U<0S6..@39K$,\=IR=O.W%=W(#<8Y]LO</#5'H]))W";
ML3DX>\!X!1LRLY&-WTQ 8+"#<DS<_ICM,/%I.&VBXF6Y+?BGSP+F908Y*VPW
MZ5%LTC$I+H4-4;"**9]7A*S-?52JC,FF: HC#BU6 28-80R/XCX^H)5M;9CI
M@72(.Q%E;7UB>=$X4E,Y3UO;:^?U'IYV=7E)=(;WOV; W33.0H,/N+;S'"A<
M7?D;KBH&B03QS [BJ;2% 29IQ.6$ZAR8H56/,+S*UDNHME6LZ 9B,/8X+8K=
M\*FJG%^XQ)7#QTF VII7[$0Z<YM>WP*N5"'9.R%0_SEV,;U]-?V"^"SB>Y*R
MT'I>#Q=981-F/<JBPU'A^0?[]I(R(C$I'2V5G-IS,L(,7647Q [ 6Q4%Q6P/
MB.(.>#!0@Z8;&6EA876E6KCV+9;NNO!^D*FYOJQPI;W4"X%@R:DD9D*Q/M/S
M<'6EH8<(GPCFUW@@BH:#T^3V6;,==FSTM],:$ 5>>O:XM?5TW/:I=7?[OG-W
MW_'04T)$(=C:7QO5V)>O<Z.BG TK7+JJ0&,+C$;-J>'V:]F7TA.S/H6&>]^8
M870:BKZUTC;85M..4**O;]NUVPD_BE*Z6BG++#@E@=J49^:_8#E:YB&5;^)E
MQRU2IJ^1)G KL\=YI[0SIUMM9>$N9;@ZB2-H05CX;^=7RO8;B&O4J>A&>DJ1
M24]9X2[D?>:L9,-!F<M0 "".D*<5DJ*<4+"@81#<X,?JD4*M'C.CT<22H*$K
MI)M4'>G_-&"73DM-EZ=2,XDR=*&G@YO%IT0[DWAO6I$9O4&.;&3;'DE-/VVX
M:8K )X.0925Y22_"/:#I=H#O+\9_L[VU,,PDGFOQ:M==U[#]1J-J=U2Q=5$]
M/Z'V>=0$%NTI?BAC;@5!757S;)+TC5^D;L4D#[=/+YARC]Z+6_1>^/1L&-6_
M4-;:,M5V1AV*TCV\"RL84]#0QN'^5=K9"DIBXD"+P;*ALH-R5(B,M2X6S.*F
MW+W&,W(]&YN5[B$.KU"!88/WRCR7G.U9GQ*^!\QF)7L3GL?Z0]7S0)Z&B:FI
MH.I$IXX@M#B5:CI--, <U)G?P#V(G(\(43C(7B&!EO%U7&CH7>+!J-G #:E)
M)'"=%T?$G3'"8+^Q29 LD ^E(#DY9J(@<+$BFQ(:R/?,@%R-%"1B]28D9.-]
MA$V!Z%QI'+$I0ZFL0VOVFAQN)'QTCEBESJW*8,9E+&091;:5&GGB<:^J>F/-
MIC6"M*6U&]&XB5BV=P1UJ5V:A%V@3>DU3FFOODML;LY%.B:9BJG21L,GQ$?G
M[J1$"/B0:[W-J?%VS*):6?L I9S(,V,YPACR\]ADSGHIL^9V=BG"D2-*4'H>
MZ4[H(.R4@HJ/U574!A64*W?-::N@1G6'+516&%;%68"Y0AN^F76:Y1(BD:B:
MJ^*R]CMFM]+\O;1<WVUJ4KV^%^.MLT-K5RL\!,T&B71Y?34+-MEV-5:\NM+"
MB\,&2@,UV&0;B$N@*>\LK-*=38C+ZCEJ5Z:C9E+QCKM/.GP(#5SOZHKOLMZ"
M95_;-1YJ-DKO6CUNUX[/1 :H# "=B4;E(5)%,\K2 3ECT) BVP\3PPD+@)L9
MX&:*=<!"LF+(%\FW$L. -2'N7*_:7]_BJFGJ)[K][.5:OTKLJ-4 '\HG!#SD
MR4]M/356;J[QX9_$W-V,$D6XV_.Z'&V[_Y6(Q3:>.K?W"Z 0&GS7JC!2^>9,
M/M*TXO+F<@&S")45N =NJ0Y8\D.6N#A8D;4]A+(E#[:MB"""D'IR@P^/[4@,
M@M0@\)/)F-Q,=*B>_D@0<'U,!,FQWY"H=8X9B&ST5A<)P*1NAU0;XL##B071
M-U,J943,N6C"/%,V2U5ZA%+N1$8[0IX9#!Y7#\7 :#CJ4(&P6Z> I0XNDE3R
MT\S9YL.:)K<"#%=R?5V1P$Y%5L>NPOW<*9?J2EEDC TZ249<NE.SNB(.Z&$<
MUT'XO,RY]N L.Q6?/5_KK:]M-T5U4<-A0&S55P#KIHS*'%BL=-K*!KSB$^("
M_!*Z^NFS%VMYHQ/SP9KVSQY-^^][2#I/B4E"GV#"@JFCM(#O0.;8CAJXJY2K
M--N^?OZDY]R2TR-5B[4^TPTE*8ZV^Q%S1)L=^0?K>U]DG$OF3W^?9,+GK<F$
ME0(6^6-OW:L!L'G^DCDA5854+"KYZ299KIK+9%1;3HVBK(F.-.IG6$/C$I>9
M+9%2S<X3"\F:E+93*Y<83 9LS? W(H>X(*F#92H *0=/9PNW81.I(YQDT2NK
M126Y-FAL3[>>59G>#765%S<^6OOK0=NVU\MG.DH[NTBA?<.X[XJ$)(JZHNJ1
MD:YW<H34*?I4OAQC@[,OR"7RB'IU$<_9DC1*2U[XE:>W2EFK*W724@R"3,D\
M:"&Q< &-[>[6TC-R3<].5%^)LA>]=NM9V)P*U92KM0CBX\>0_D&K2+&Q\);%
MT!D5;#39=$^A8UF$N:^>XJQ1Z:XT$EV"-[:GBRG62 ["-*'"D$Q7/A^C?<9I
M/?? /%I0I*/Q2&WS27O:JL[ *NY/\R'P4(K%(7?,Q^P=;O&?LL7:<:/V"*:
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M]S#"37.HFRINX_ ,B5J%F'WT"5?_7FU@<$K:C248X>>?HF(0_2MX;_H+(<!
M\'N4?XU+G1D5!5<=4\,F%S59X;T= 0BJKW?O-ZA>F$@#%G\R&P=D&%/+>QR)
MZ1*@6B2"XII&HA2+'6':^, <U,I0WK8DI1@]SLT1-&;32SII?"4&J[R&=F5J
MXR_]-(YR-A%-,H^L#C?YA%E3.U2=&(2_9K.2A  !<A2H]AO/Q0C,O20U7:!T
MNU^_OZJ5V+@(M@=8PW6$MRE,*X"!Y^?481E3XB,R +P4(Z%CA5_J6R8TZ3PI
MDHHZ'&CO1KBZHAJGPPQ!.\C&!&MAVX1YRZ0F%:=%3/48%NG)Z5=6JQ)T(UW6
M:=6J"Z577:S752K4F8KOI#2QF^26M::[99-+E9T 4W-RIQ(N&YD"=&./5$/:
M%R8DWMBM6IQ!(F-<19=B,^U-7)9"PKLO%3[?EBKP:73-FO1W&_2O.6V;G<"K
M*UX7,#0=N8MUS7!L<,>*#4(Q?^0:4=]*O@79."V)-]J3:-',0O4:G9-6R6A
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M]$=MI.<&80,,\_/A7_#EA[/?/_[V?P%02P,$%     @ QH*>4#]=2_JY5P
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M7:48 &MQ5F^>PD[B99T[N]T4&=!= "*5:6.$6)*D$Z#%H%2Q,Q2U*L\C'&@
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MM:W'KJG&.9)Y-L:J*,FF,?;Z.H,OZ1BX%"M0)13%%521B(B/4VKBE,'_8I"
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MDN\U/6G5U;1YH&J.&O6Y*?/M^D>N!31: [)Q]<ITV[[K"W.*8!<%AK B4J*
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MQ-_;BDEE,<>P\-[I6;?G[1T?G@"U?"1"^S?O]^/3_X;/3D^.3TG_6%U9XW1
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MBJ0DV]'!*EV1N"5++HF)-_MM"([(24  P2&)^?7[NF<&&$"4?"5.:A.7+0O
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MU9\U7BT@K:K)^P0D4AA*ZV(2V;T&B*G*9;KB3)S;;?B)NW!TLROJL;A.W@_
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M8!1P_SG;; "-!)0!+PBH"/"A00@:W&X"Y   A('? _P1D \"A<$12!2_P,Y
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M     &)I:6(M,C R,# T,C<N>'-D4$L! A0#%     @ QH*>4(!.-&YB!@
M240  !4              ( !E ,  &)I:6(M,C R,# T,C=?;&%B+GAM;%!+
M 0(4 Q0    ( ,:"GE#9RK\^NP0   LK   5              "  2D*  !B
M:6EB+3(P,C P-#(W7W!R92YX;6Q02P$"% ,4    " #&@IY0V*]994H3  ""
M>   #@              @ $7#P  9#@U-S<S.60X:RYH=&U02P$"% ,4
M" #&@IY0E>T(KY=E  #K+P( $               @ &-(@  9#@U-S<S.61E
M>#$Q+FAT;5!+ 0(4 Q0    ( ,:"GE _74OZN5<  $=, @ 0
M  "  5*(  !D.#4W-S,Y9&5X-#(N:'1M4$L! A0#%     @ QH*>4/"%Q$4E
M#P  @SH  !               ( !.>   &0X-3<W,SED97@U,2YH=&U02P$"
M% ,4    " #&@IY0LOC#M_X%  "*!@  &0              @ &,[P  9S@U
L-S<S.6<P-#,P,#,P,C S-S,P+FIP9U!+!08     "  (  ("  #!]0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6628282288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Apr. 27, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 27,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Biogen Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0112644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">225 Binney Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">679-2000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0005 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIIB<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>14
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M/_QNPM9I<S#_V/@JV+7PZRZZ+U!+ P04    " #&@IY0F5R<(Q &  "<)P
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M"B]-\K!EG3>*G.[V9ZC%H-[.!?>_1/$#4$L#!!0    ( ,:"GE 6;2-_0P$
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " #&@IY04>_82.X    K @  $0
M            @ &9 0  9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #&
M@IY0F5R<(Q &  "<)P  $P              @ &V @  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( ,:"GE!XMPG>G0(  ),+   8
M  "  ?<(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #&
M@IY0S^5Z?T8"  #D!0  %               @ '*"P  >&PO<VAA<F5D4W1R
M:6YG<RYX;6Q02P$"% ,4    " #&@IY0NJ$YBM<!   R!@  #0
M    @ %"#@  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ,:"GE 6;2-_0P$
M #P"   /              "  400  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " #&@IY0_\ F"+T   "% @  &@              @ &T$0  >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #&@IY0"X_8 R$!  !7
M!   $P              @ &I$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    "@ * ( "  #[$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d857739d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d857739d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "biib-20200427_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "biib-20200427_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "biib-20200427.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "biib",
   "nsuri": "http://www.biogenidec.com/20200427",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d857739d8k.htm",
      "contextRef": "duration_2020-04-27_to_2020-04-27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d857739d8k.htm",
      "contextRef": "duration_2020-04-27_to_2020-04-27",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.biogenidec.com//20200427/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>d857739d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="biib-20200427.xsd" xlink:type="simple"/>
    <context id="duration_2020-04-27_to_2020-04-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2020-04-27</startDate>
            <endDate>2020-04-27</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2020-04-27_to_2020-04-27">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2020-04-27_to_2020-04-27"
      id="Hidden_dei_EntityCentralIndexKey">0000875045</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2020-04-27_to_2020-04-27">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2020-04-27_to_2020-04-27">2020-04-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2020-04-27_to_2020-04-27">Biogen Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2020-04-27_to_2020-04-27">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2020-04-27_to_2020-04-27">0-19311</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2020-04-27_to_2020-04-27">33-0112644</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2020-04-27_to_2020-04-27">225 Binney Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="duration_2020-04-27_to_2020-04-27">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2020-04-27_to_2020-04-27">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2020-04-27_to_2020-04-27">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2020-04-27_to_2020-04-27">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2020-04-27_to_2020-04-27">679-2000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2020-04-27_to_2020-04-27">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2020-04-27_to_2020-04-27">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2020-04-27_to_2020-04-27">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2020-04-27_to_2020-04-27">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2020-04-27_to_2020-04-27">Common Stock, $0.0005 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2020-04-27_to_2020-04-27">BIIB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2020-04-27_to_2020-04-27">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2020-04-27_to_2020-04-27">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
